Interventions for preventing oral mucositis for patients with cancer receiving treatment by Worthington, Helen V. et al.
                                                              
University of Dundee
Interventions for preventing oral mucositis for patients with cancer receiving treatment
Worthington, Helen V.; Clarkson, Janet; Bryan, Gemma; Furness, Susan; Glenny, Anne-
Marie; Littlewood, Anne; McCabe, Martin G.; Meyer, Stefan; Khalid, Tasneem
Published in:
Cochrane Database of Systematic Reviews
DOI:
10.1002/14651858.CD000978
Publication date:
2006
Document Version
Publisher's PDF, also known as Version of record
Link to publication in Discovery Research Portal
Citation for published version (APA):
Worthington, H. V., Clarkson, J. E., Bryan, G., Furness, S., Glenny, A-M., Littlewood, A., ... Khalid, T. (2006).
Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database of
Systematic Reviews. 10.1002/14651858.CD000978
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 15. Mar. 2016
Interventions for preventing oral mucositis for patients with
cancer receiving treatment (Review)
Clarkson JE, Worthington HV, Eden OB
This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library
2006, Issue 1
http://www.thecochranelibrary.com
1Interventions for preventing oral mucositis for patients with cancer receiving treatment (Review)
Copyright © 2006 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd
T A B L E O F C O N T E N T S
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3CRITERIA FOR CONSIDERING STUDIES FOR THIS REVIEW . . . . . . . . . . . . . . . . . .
3SEARCH METHODS FOR IDENTIFICATION OF STUDIES . . . . . . . . . . . . . . . . . . .
4METHODS OF THE REVIEW . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
5DESCRIPTION OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6METHODOLOGICAL QUALITY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
10DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
11AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
12NOTES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
12POTENTIAL CONFLICT OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . .
12ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
12SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
12REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
19TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
19Characteristics of included studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
33Characteristics of excluded studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
35ADDITIONAL TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
35Table 01. Quality assessment of trials . . . . . . . . . . . . . . . . . . . . . . . . . . . .
37Table 02. Data from parallel group studies for comparisons involving cross-over studies . . . . . . . . . . .
38Table 03. Data from cross-over studies . . . . . . . . . . . . . . . . . . . . . . . . . . .
39Table 04. Results from parallel group and cross-over studies . . . . . . . . . . . . . . . . . . . .
41ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
41Comparison 01. Active treatment versus placebo/no treatment . . . . . . . . . . . . . . . . . . .
41Comparison 02. Side effects . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
41INDEX TERMS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
41COVER SHEET . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
42GRAPHS AND OTHER TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
43Analysis 01.01. Comparison 01 Active treatment versus placebo/no treatment, Outcome 01 mucositis (absent versus
present) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
46Analysis 01.02. Comparison 01 Active treatment versus placebo/no treatment, Outcome 02 mucositis (0-1 versus 2+)
48Analysis 01.03. Comparison 01 Active treatment versus placebo/no treatment, Outcome 03 mucositis (0-2 versus 3+)
51Analysis 02.01. Comparison 02 Side effects, Outcome 01 amifostine . . . . . . . . . . . . . . . . .
53Analysis 02.02. Comparison 02 Side effects, Outcome 02 GM-CSF . . . . . . . . . . . . . . . . .
iInterventions for preventing oral mucositis for patients with cancer receiving treatment (Review)
Copyright © 2006 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd
Interventions for preventing oral mucositis for patients with
cancer receiving treatment (Review)
Clarkson JE, Worthington HV, Eden OB
This record should be cited as:
Clarkson JE, Worthington HV, Eden OB. Interventions for preventing oral mucositis for patients with cancer receiving treatment. The
Cochrane Database of Systematic Reviews 2003, Issue 3. Art. No.: CD000978. DOI: 10.1002/14651858.CD000978.
This version first published online: 21 July 2003 in Issue 3, 2003.
Date of most recent substantive amendment: 23 May 2003
A B S T R A C T
Background
Treatment of cancer is increasingly more effective but is associated with short and long term side effects. Oral side effects remain a
major source of illness despite the use of a variety of agents to prevent them. One of these side effects is oral mucositis (mouth ulcers).
Objectives
To evaluate the effectiveness of prophylactic agents for oral mucositis in patients with cancer receiving treatment, compared with other
potentially active interventions, placebo or no treatment.
Search strategy
The Cochrane Oral Health Group’s Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE and
EMBASE were searched. Reference lists from relevant articles were scanned and the authors of eligible studies were contacted to identify
trials and obtain additional information.
Date of most recent searches June 2002.
Selection criteria
Trials were selected if they met the following criteria: design - random allocation of participants; participants - anyone with cancer
receiving chemotherapy or radiotherapy treatment for cancer; interventions - agents prescribed to prevent oral mucositis; outcomes -
prevention of mucositis, pain, amount of analgesia, dysphagia, systemic infection, length of hospitalisation, cost and patient quality of
life.
Data collection and analysis
Information regarding methods, participants, interventions and outcome measures and results were independently extracted, in dupli-
cate, by two reviewers. Authors were contacted for details of randomisation and withdrawals and a quality assessment was carried out.
The Cochrane Oral Health Group statistical guidelines were followed and relative risk values calculated using random effects models.
Main results
One hundred and nine studies were eligible. Fifty-seven were excluded for various reasons, usually as there was no useable information
on mucositis. Of the 52 useable studies all had data for mucositis comprising 3594 randomised patients. Interventions evaluated were:
acyclovir, allopurinol mouthrinse, amifostine, antibiotic pastille or paste, benzydamine, camomile, chlorhexidine, clarithromycin, folinic
acid, glutamine, GM-CSF, hydrolytic enzymes, ice chips, oral care, pentoxifyline, povidone, prednisone, propantheline, prostaglandin,
sucralfate and traumeel. Of the 21 interventions included in trials, nine showed some evidence of a benefit (albeit sometimes weak) for
either preventing or reducing the severity of mucositis. Interventions where there was more than one trial and a significant difference
compared with a placebo or no treatment were allopurinal with unreliable evidence for a reduction in the severity of mucositis OR =
0.01 (95% CI: 0 to 0.03), amifostine provided minimal benefit in preventing mucositis RR = 0.95 (95% CI: 0.91 to 0.99), antibiotic
paste or pastille demonstrated a moderate benefit in preventing mucositis RR = 0.87 (95% CI: 0.79 to 0.97), GM-CSF prevented
mucositis RR = 0.51 (95% CI: 0.29 to 0.91), hydrolytic enzymes reduced the severity of mucositis RR = 0.49 (95% CI: 0.30 to 0.81),
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and ice chips prevented mucositis OR = 0.42 (95% CI: 0.19 to 0.93). Other interventions showing some benefit with only one study
were: benzydamine, oral care protocols and povidone.
The NNT to prevent one patient experiencing mucositis over a baseline incidence of 60% for amifostine is 33 (95% CI: 20 to 100),
antibiotic paste or pastille 13 (95% CI: 8 to 50), GM-CSF 3 (95% CI: 2 to 20) and ice chips 5 (95% CI: 2 to 31). When the baseline
incidence is 40%/90% the NNTs for amifostine are 50/20, for antibiotic paste or pastille 20/8, for GM-CSF 5/2 and for ice chips
6/10.
The general reporting of RCTs was poor. However, the quality of the randomisation improved when the authors provided additional
information.
Authors’ conclusions
Several of the interventions were found to have some benefit at preventing or reducing the severity of mucositis associated with cancer
treatment. The strength of the evidence was variable and implications for practice include consideration that benefits may be specific
for certain cancer types and treatment. There is a need for well designed and conducted trials with sufficient numbers of participants
to perform subgroup analyses by type of disease and chemotherapeutic agent.
P L A I N L A N G U A G E S U M M A R Y
Several therapies appear to either prevent or reduce the severity of mouth ulcers caused by chemotherapy or radiotherapy for cancer
Treatment for cancer (including bone marrow transplant) can cause oral mucositis (severe ulcers in the mouth). This can cause
discomfort, pain, difficulties in eating, and a longer stay in hospital. Different strategies are used to try and prevent this condition, and
the review of trials found that some of these are effective. Effective treatments include several drugs which can be taken as tablets and
others which can be added to the cancer treatment regimen. Other interventions that were effective were a mouthwash medicated with
allopurinol and sucking ice chips before and during the cancer treatment.
B A C K G R O U N D
Treatment of solid malignant tumours and the leukaemias with
cytotoxic chemotherapy and/or radiotherapy is becoming increas-
ingly more effective but it is associated with short and long term
side effects. Among the clinically important acute side effects is the
disruption in the function and integrity of the mouth. The con-
sequences of this include severe ulceration (mucositis) and fungal
infection of the mouth (oral candidiasis, thrush). These disease
and treatment induced complications may also produce oral dis-
comfort and pain, poor nutrition, delays in drug administration,
increased hospital stays and costs and in some patients life threat-
ening infection (septicaemia).
Oral complications remain a major source of illness despite the
use of a variety of agents to prevent them. There are variations in
usage between cancer centres in terms of the mouthcare regimen
used. Compliance with recommended use of product is variable
and there are conflicting reports of the effectiveness of prophylac-
tic agents. The qualitative and quantitative benefits, side effects
and costs of oral therapies are of importance to the cancer teams
responsible for the treatment of patients.
There have been several traditional reviews published and most
of these present a general discussion for both chemotherapy and
radiotherapy induced oral side effects (De Pauw 1997; Denning
1992; Lortholary 1997; Stevens 1995; Symonds 1998; Verdi 1993;
White 1993). The conclusions drawn and recommendations made
vary from advocating a particular therapy to recommending oral
care procedures that have not been systematically investigated.
Two systematic reviews have focused on the prevention of oral
mucositis in patients with cancer. One older review published in
1998 concluded that for most strategies reviewed there is insuffi-
cient evidence to draw any conclusions regarding their effective-
ness (Kowanko 1998). The other more recent review focused on
patients with head and neck cancer only and the main analysis
combined all the interventions in one meta-analysis and found a
beneficial effect of prophylactic interventions (Sunderland 2001).
A previous version of this Cochrane review looked at the use of
oral and prophylactic agents for the prevention of oral mucosi-
tis and oral candidiasis in patients with cancer treated by chemo-
therapy (Clarkson 2003a). The review concluded that there was
some evidence that using ice chips during the chemotherapy treat-
ment was effective in preventing mucositis. This updated review
broadens the oral mucositis part of that review and looks at the
prevention of oral mucositis in patients receiving any treatment
for cancer, including patients with all types of cancer, including
head and neck cancer, and including comparisons between any
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interventions for prevention. A second review updating the pre-
vention of oral candidiasis has also been recently published on
The Cochrane Library (Worthington 2003a). These reviews form
part of a series of four Cochrane reviews on the prevention and
treatment of oral mucositis and oral candidiasis (Clarkson 2003b;
Worthington 2003b).
O B J E C T I V E S
To evaluate the effectiveness of interventions (which may include
placebo or no treatment) for the prevention of oral mucositis in
patients with cancer receiving chemotherapy and/or radiotherapy.
The following primary null hypothesis was tested for comparisons
between groups receiving interventions to prevent oral mucositis
during cancer treatment:
There is no difference in the proportion of patients acquiring oral
mucositis during cancer treatment.
In this review we proposed to address the hypothesis of no differ-
ence between groups treated for oral mucositis for the following
outcomes if data were available:
• Relief of pain
• Amount of analgesia
• Relief of dysphagia
• Incidence of systemic infection
• Days of stay in hospital
• Cost of oral care
• Patient quality of life.
The following subgroup analyses were proposed:
• Cancer type (leukaemia, head and neck, other solid tumours
and mixed)
• Age group (adults, children or both).
C R I T E R I A F O R C O N S I D E R I N G
S T U D I E S F O R T H I S R E V I E W
Types of studies
Only randomised controlled trials were eligible for inclusion in
this review, including both cross-over and parallel group studies.
Types of participants
Anyone with cancer who received chemotherapy and/or radiother-
apy.
Types of intervention
Active agents: any agent prescribed prophylactically for oral mu-
cositis.
Control: may be placebo or no treatment, or another active inter-
vention.
Types of outcome measures
The following outcomes were considered in this review:
• Mucositis (at all levels of severity) (ulcers)
• Relief of pain
• Amount of analgesia
• Relief of dysphagia
• Incidence of systemic infection
• Days of stay in hospital
• Cost of oral care
• Patient quality of life.
S E A R C H M E T H O D S F O R
I D E N T I F I C A T I O N O F S T U D I E S
See: Oral Health Group methods used in reviews.
This review is part of a series of four reviews on the prevention
and treatment of oral candidiasis and oral mucositis in patients
with cancer, and the same search strategy was used for all four
reviews.
The search attempted to identify all relevant trials irrespective of
language. Papers not in English were translated by members of
the Cochrane Collaboration.
Electronic searching - the databases searched were:
• The Cochrane Oral Health Group’s Trials Register (May 2002)
• The Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library Issue 2, 2002)
• MEDLINE (from 1966 to May 2002)
• EMBASE (from 1974 to June 2002).
Sensitive search strategies were developed for each database
(available from the authors on request) using a combination of
free text and Mesh terms.
The search strategy for CENTRAL is given as an example below:
1.NEOPLASMS*:ME
2.LEUKEMIA* ME
3.LYMPHOMA* ME
4.RADIOTHERAPY*:ME
5.BONE-MARROW-TRANSPLANTATION:ME
6.neoplasm*
7.cancer*
8.(leukemi* OR leukaemi*)
9.(tumour* OR tumor*)
10.malignan*
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11.neutropeni*
12.carcino*
13.adenocarcinoma*
14.lymphoma*
15.radioth* OR radiat* OR irradiat* OR radiochemo*
16.((bone NEXT marrow) NEAR transplant*)
17.chemo*
18.#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR
#9 OE #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16
OR #17
19. STOMATITIS*:ME
20.CANDIDIASIS-ORAL:ME
21.stomatitis
22.mucositis
23.oral AND cand*
24.oral NEAR mucos*
25.oral AND fung*
26.mycosis OR mycotic OR thrush
27.#19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR
#26
28.#18 AND #27
Only handsearching carried out by the Cochrane Collaboration
is included in the search (see master list http://www.cochrane.
org).
The reference list of related review articles and all articles
obtained were checked for further trials. Authors of trial reports
and specialists in the field known to the reviewers were written to
concerning further published and unpublished trials. The review
will be updated every 2 years using the Cochrane Oral Health
Group’s Trials Register, CENTRAL, MEDLINE and EMBASE.
Date of most recent searches June 2002 (CENTRAL) (The
Cochrane Library Issue 2, 2002).
M E T H O D S O F T H E R E V I E W
The titles and abstracts (when available) of all reports identified
through the searches were scanned by two reviewers (Jan Clarkson
(JC) and Helen Worthington (HW)). Full reports were obtained
for trials appearing to meet the inclusion criteria, or for which
there was insufficient information in the title and abstract to make
a clear decision. The full reports obtained from all the electronic
and other methods of searching were assessed independently, in
duplicate, by these two reviewers to establish whether the trials
met the inclusion criteria or not. Disagreements were resolved by
discussion.
The quality assessment of included trials was undertaken
independently and in duplicate by two reviewers as part of the data
extraction process. Included trials were assessed on three criteria,
concealed allocation of treatment (A = adequate, B = unclear, C
= inadequate), blinding of patients (0 = no, 1 = yes, 2 = unclear),
carers and outcome assessors (0 = no, 1 = yes, 2 = unclear), and
information on reasons for withdrawal by trial group (0 = no,
1 = yes). The agreement between the reviewers was assessed by
calculating the kappa score.
Data were extracted by two reviewers independently using specially
designed data extraction forms. The characteristics of the trial
participants, interventions and outcomes in the included trials are
presented in the study tables. Mucositis may be dichotomised at
different levels of severity. In order to maximise the availability of
similar outcome data we recorded the number of patients in each
category of mucositis. Pain was assessed on visual analogue scales
(0 to 100), the means and standard deviations for each group were
recorded. The duration of trials and timing of assessments were
recorded in order to make a decision about which to include for
commonality. We also recorded the country where the trial was
conducted and whether a dentist was involved in the investigation.
Some of the authors were contacted for clarification or for further
information.
DATA SYNTHESIS
For dichotomous outcomes, the estimates of effect of an
intervention were expressed as relative risks together with 95%
confidence intervals, apart from meta-analyses including cross-
over studies, where odds ratios were used.
We planned to investigate clinical heterogeneity by examining
the different cancer types and age groups, however there were
insufficient trials to undertake this. Meta-analyses were done
only with studies of similar comparisons reporting the same
mucositis outcome measures. Relative risks were combined for
dichotomous data using random effects models. The significance
of any discrepancies in the estimates of the treatment effects from
the different trials was assessed by means of Cochran’s test for
heterogeneity.
CROSS-OVER TRIALS
The treatment effects from cross-over trials were combined with
those from parallel group trials where appropriate, using the data
from both periods of the cross-over studies. Stata was used for
this analysis, outside RevMan (Elbourne 2002). Where data for
the cross-tabulation of pairs was not available, all possible paired
comparisons for each study were calculated. In situations where
more than one data cross-tabulation was possible, the scenarios
taking the most extreme cases were considered and incorporated
into any meta-analysis.
It was planned to undertake a sensitivity analysis to examine the
effect of concealed allocation and blind outcome assessment on the
overall estimates of effect. However there were insufficient trials
in any specific intervention group to undertake this.
We proposed a priori to conduct subgroup analyses for different
cancer types (head and neck, other solid tumours, leukaemia and
mixed) and age groups (children, adults and mixed). However
there were insufficient trials by intervention type to do this.
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D E S C R I P T I O N O F S T U D I E S
CHARACTERISTICS OF THE TRIAL SETTINGS AND IN-
VESTIGATORS
See ’Characteristics of included studies’ table.
See ’Characteristics of excluded studies’ table.
There were 109 trials eligible for inclusion in the review. Fifty-
seven of these trials were excluded for the following reasons:
• abstracts giving insufficient information (15 trial reports: An-
tonadou 1998; Costa 1999; Etiz 1998; Epstein 1999; Evans
1990; Harris 1995; Leong 1995; Levendag 1998; Marcial 1994;
Okuno 1998; Pfeiffer 1989; Pouli 1999; Suc 1999; Vitello
2000; Wymenga 1999)
• mucositis data presented in the form of mean scores, which
were not in an appropriate form for this review (23 trial re-
ports: Apaydin 1996; Barasch 1995; Bensadoun 1999; Cowen
1997; Dudjak 1987; Epstein 1989; Epstein 1992; Epstein 1994;
Etiz 2000; Feber 1996; Grotz 2001; Hanson 1997; Jebb 1995;
Kenny 1990; Lievens 1998; Lopez 1994; McGaw 1985; Prada
1985; Raether 1989; Rutkauskas 1993; Samaranayake 1988;
Verdi 1995; Weisdorf 1989)
• mucositis data not in appropriate form for other reasons than
that given above (eight trial reports: Anderson 1998b; Chi 1995;
Decker-Baummann 1999; Epstein 1986; Epstein 2001; Nicholl
1995; Niibe 1985b; Vacha 1999)
• data presented as episodes rather than patients, where patients
were re-entered into the study, so data not independent (two
trials: Hickey 1982; Karthaus 1998)
• major change to protocol half way through study (one trial:
Okuno 1997)
• investigation of new cancer treatment, where mucositis was mi-
nor side effect (one trial: Cunningham 1995)
• qualitative assessment of mucositis (one trial: McIlroy 1996)
• comparing different radiotherapy regimens (one trial: Falcone
2001)
• randomised controlled trial (RCT) design fault (two trials: Erk-
isi 1996; Rocke 1993)
• not RCT (three trials: Edelman 1998; Fahlke 1999; Sato 1997).
Of the 52 included trials 46 were designed as parallel group stud-
ies and six as cross-over studies (Anderson 1998; Dozono 1989;
Jebb 1994; Loprinzi 1990; Mahood 1991; Pfeiffer 1990). None
of the published reports gave the ’paired’ data in an appropriate
form to be used in a meta-analysis. All the authors were contacted
and replies were received supplying data for three studies (Ander-
son 1998; Loprinzi 1990; Mahood 1991). Other data had to be
extracted as outlined in the methods section.
Of the 52 included trials all included data on assessment of mucosi-
tis. Nineteen (37%) trials were conducted in USA or Canada, 21
(40%) in Europe, three trials in Japan, two in India and one in each
of the following countries: Mexico, Taiwan, China, Turkey, Israel,
Hong Kong and one multicentre study in the USA and European
countries. Only two trials were muticentre that included patients
in more than one country (Brizel 2000; Nemunaitis 1995). Thirty-
one trials received external funding, with this being unclear in a
further 11 trials and with no external funding evident in 10 trials.
A dentist was involved in 14 of the trials and in six trials the patient
was involved in the clinical outcome measure.
CHARACTERISTICS OF THE PARTICIPANTS
Forty-three (83%) of the included trials recruited only adult pa-
tients, seven included both adults and children (with a difference
in age as large as 1-70 years), only one trial was conducted solely
on paediatric patients (Shenep 1988) and the age range was un-
clear in one study (Mahood 1991). The type of cancer for which
patients were being treated was exclusively head and neck cancer
in 25 trials (48%), leukaemia in five trials, solid tumours in 10
trials and a combination of haematological and solid tumours in
nine trials, the cancer type being unclear in three trials. The radio-
therapy and/or chemotherapy regimen was described in most of
the trials though the chemotherapeutic agents were not always de-
scribed in full detail. Of the five trials involving patients treated for
leukaemia three were studies involving patients receiving a bone
marrow transplant and the corresponding figure for mixed cancers
was five. The chemotherapy regimen included 5-FU in six of the
10 trials for patients with solid tumours although it was not al-
ways clear if the dose was in a bolus or continuous form. Trials in
which patients received radiotherapy generally gave information
about the total and daily or weekly dose. Total radiotherapy for
head and neck cancer was generally 60-74 Gy and the karnofsky
performance > 60.
CHARACTERISTICS OF INTERVENTIONS
All of the 52 trials provided a clear description of the interven-
tions including the dose and method of administration for the test
and control group. The dosage of the test agents varied for sim-
ilar products. All the trials used either a placebo (28 trials), a no
treatment control (18 trials), or water (two trials), glycine, sugar
solution, polycal, saline (one trial each) as a control group. Two
trials included in the no treatment control group tested different
oral care protocols and in each case one group received limited
oral hygiene (Borowski 1994; Shieh 1997).
The interventions for the 52 studies assessing oral mucositis were:
• acyclovir (Bubley 1989)
• allopurinol mouthrinse (Dozono 1989; Loprinzi 1990)
• amifostine (Antonadou 2002; Bourhis 2000; Brizel 2000;
Buntzel 1998; Koukourakis 2000; Niibe 1985)
• antibiotic pastille or paste (Symonds 1996; Wijers 2001)
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• benzydamine ( Prada 1987)
• camomile (Fidler 1996)
• chlorhexidine (Dodd 1996; Ferretti 1988; Ferretti 1990; Foote
1994; Spijkervet 1989; Wahlin 1989)
• clarithromycin antibiotic (Yuen 2001)
• folinic acid (Erlichman 1988)
• glutamine (Anderson 1998; Dickson 2000; Huang 2000; Jebb
1994; Okuno 1999)
• GM-CSF (Cartee 1995; Crawford 1999; Katano 1995; Makko-
nen 2000; Nemunaitis 1995; Van der Leslie 2001; Schneider
1999)
• hydrolytic enzymes (Gujral 2001; Kaul 1999)
• ice chips (Cascinu 1994, Mahood 1991)
• oral care (Borowski 1994; Shieh 1997)
• pentoxifyline (Attal 1993)
• povidone (Rahn 1997)
• prednisone (Leborgne 1997)
• propantheline (Ahmed 1993) anticholinergic
• prostaglandin (Duenas 1996; Labar 1993)
• sucralfate (Carter 1999; Cengiz 1999; Franzen 1995; Makko-
nen 1994; Pfeiffer 1990; Shenep 1988)
• traumeel (Oberbaum 2001).
CHARACTERISTICS OF OUTCOME MEASURES
Mucositis
All trials used a graded scale to record the severity of mucositis.
Most described the index used or referred to published criteria,
mainly WHO or EROTC. Scales were similar to the five point
WHO scale ranging from 0 (normal) to 4 (severe). The cate-
gories initially relate to visible changes in the mucosa and gradually
record pain and inability to eat solid foods. Thirty-four studies
provided information for an absent versus present dichotomy, 29
trials provided information dichotomising at grade 1 and 30 trials
dichotomising at grade 2. The duration of the trials varied from
a few days up a year after treatment. The interval during which
mucositis was recorded varied from 5 to 90 days or until the end
of the radiotherapy, or the leukocyte count was above 8000 mm³.
Several studies presented data at different time points, with the
median time point being 28 days. The nearest assessment to 28
days was used for all studies.
There was little consistency on the other outcome measures re-
ported:
• Oral hygiene measures (Borowski 1994; Wahlin 1989)
• Relief of pain (Carter 1999; Cengiz 1999; Franzen 1995; Pfeif-
fer 1990;Van der Leslie 2001; Wijers 2001)
• Use of analgesia (morphine)(Attal 1993; Carter 1999; Cengiz
1999; Ferretti 1988; Makkonen 2000; Van der Leslie 2001)
• Duration or severity of dysphagia (Antonadou 2002; Bourhis
2000; Buntzel 1998; Cengiz 1999; Franzen 1995; Gujral 2001;
Pfeiffer 1990; Prada 1987; Symonds 1996)
• Use of pareneral nutrition or feeding tube (Bourhis 2000; Carter
1999; Carter 1999; Dickson 2000; Yuen 2001)
• Incidence of systemic infection or use of antibiotics (Attal 1993;
Borowski 1994; Crawford 1999; Ferretti 1990; Shenep 1988;
Van der Leslie 2001; Yuen 2001)
• Febrile episodes (Ahmed 1993; Attal 1993; Borowski 1994;
Duenas 1996; Katano 1995; Labar 1993; Shenep 1988; Van
der Leslie 2001; Wahlin 1989; Yuen 2001)
• Blood changes (Ahmed 1993; Antonadou 2002; Buntzel 1998;
Cartee 1995; Crawford 1999; Van der Leslie 2001)
• Treatment interruption (Antonadou 2002; Carter 1999;
Makkonen 1994)
• Days of stay in hospital (Attal 1993; Dickson 2000; Duenas
1996; Van der Leslie 2001)
• Toxicity - nausea/vomiting/constipation/diarrohea (Antonadou
2002; Bourhis 2000; Brizel 2000; Cengiz 1999; Dickson 2000;
Duenas 1996; Labar 1993; Shenep 1988; Yuen 2001)
• Toxicity - skin changes (Bourhis 2000; Buntzel 1998; Buntzel
1998; Gujral 2001; Shenep 1988; Yuen 2001)
• Toxicity - unspecific (Fidler 1996; Makkonen 1994; Makkonen
2000; Okuno 1999)
• Xerostomia (Brizel 2000; Buntzel 1998; Cengiz 1999)
• Cost (Dodd 1996)
• Patient quality of life (no trials)
• Death (Ahmed 1993; Attal 1993; Brizel 2000; Ferretti 1988;
Labar 1993; Makkonen 2000).
M E T H O D O L O G I C A L Q U A L I T Y
There was excellent agreement between the scores assigned by the
two reviewers, with kappa values for concealment 0.88, patient
blind 0.85, carer blind 0.90, outcome assessor blind 0.68 and clear
description of withdrawals 0.72.
The results of the quality assessment for concealment of randomi-
sation, blinding of outcome assessor and whether there is a clear ex-
planation of drop outs by study group are given in ’Additional Ta-
ble 01’, using the criteria outlined in the methods section. Changes
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in the quality assessment due to information from authors are
shown by putting the initial assessment in parenthesis.
There was variation in the quality of the studies using the re-
ported information and additional information provided by au-
thors. Overall, 54% of the trials had adequate concealment of ran-
domisation, in 58% the patient was blinded to treatment group,
52% the provider of treatment blinded, 60% the assessor blinded
and in 63% adequate information of withdrawals was given with
the reason specified by study group. Sixty per cent of trials (31/52)
reported some external support and of these 19 acknowledged as-
sistance from pharmaceutical companies. The quality of trials var-
ied slightly in relation to funding with 68% of those funded hav-
ing adequate allocation concealment compared with 33% in the
unfunded trials (chi squared p-value = 0.015). However no other
significant differences were found between funded and unfunded
trials. Funded trials are more likely to use central randomisation
by a statistician.
Twenty-four out of 44 (55%) investigators replied to our letters
requesting further information and this changed the allocation
concealment assessments from B to A in nine studies. Information
provided about blinding and withdrawals changed the quality as-
sessment scores for five trials and data were provided from four
trials (Anderson 1998; Leborgne 1997; Loprinzi 1990; Mahood
1991).
R E S U L T S
109 reports of trials were initially identified as eligible according
to the defined criteria for study design, participants, interventions
and outcomes. The total number of included trials was 52; there
were five duplicate reports and 57 studies were excluded, as the
data presented were not in an accessible form for this review. See
’Characteristics of excluded studies’ table for further information
on this.
Of the 52 included studies all had data for mucositis appropriate
for this review comprising 3594 randomised patients.
The interventions involving cross-over trials are allopurinol, glu-
tamine, ice chips and sucralfate. As it was not possible to incor-
porate these trials using RevMan software, the data and analysis
for these interventions appears in the ’Additional Tables 2 to 4’.
The remainder of the results section presents the results relating
to each intervention in alphabetical order.
• Acyclovir versus placebo (MetaView ’Comparison 01’, ’Out-
come 01’)
One trial compared acyclovir with a placebo (Bubley 1989). Data
were provided for the dichotomy of mucositis 0 versus 1+. No
statistically significant differences were found and therefore there
is insufficient evidence to support or refute acyclovir as more or
less effective than placebo.
• Allopurinal versus placebo/no treatment (’Additional Table 03
and Table 04’)
Two trials, both designed as cross-over studies, compared allopuri-
nal mouthrinse with placebo or no treatment (Dozono 1989; Lo-
prinzi 1990). The pooled meta-analyses at both mucositis 0 versus
1+, and 0-1 versus 2+ dichotomies were non-significant, however
the dichotomy 0-2 versus 3+ gave rise to a significant odds ratio
of approximately zero, (95% confidence interval (CI): 0, 0.03)
which was based on 34 adults with solid tumors, suggesting that
allopurinal may reduce severe mucositis, when compared with a
placebo. Both trials had adequate concealment of allocation, one
had a blinded outcome assessment and there were no drop outs in
either trial.
• Amifostine versus placebo/no treatment (MetaView ’Compar-
ison 01’, ’Outcome 01, 02, 03’)
Six trials compared amifostine with a placebo (Niibe 1985) or no
treatment (Antonadou 2002, Bourhis 2000, Brizel 2000, Buntzel
1998, Koukourakis 2000). All trials recruited adults with head and
neck cancer being treated with radiotherapy. Three trials provided
data for mucositis at the level of 0 versus 1+, however, only one
trial provided estimable data (Brizel 2000) because every patient
experienced mucositis in the other two. There was a significant
benefit for amifostine preventing mucositis in this trial with rela-
tive risk (RR) = 0.95 (95% CI: 0.91 to 0.99). At the dichotomy 0-
1 versus 2+ one trial was significant (Brizel 2000) and in the pooled
meta-analysis the five trials provided homogeneous data (Anton-
adou 2002; Bourhis 2000; Brizel 2000; Koukourakis 2000; Niibe
1985) demonstrating amifostine as more effective than placebo or
no treatment at preventing mucositis RR = 0.83 (95% CI: 0.72
to 0.97, chi squared = 4.34, df = 3, p = 0.23). Two of the five
trials providing data for the dichotomy of mucositis of 0-2 ver-
sus 3+ were significant (Antonadou 2002; Buntzel 1998) however,
the pooled meta-analysis failed to reach significance (p = 0.07)
and did not support amifostine as being more effective than no
treatment at reducing the severity of mucositis RR = 0.54 (95%
CI: 0.27 to 1.06, chi squared = 26.01, df = 4, p < 0.0001). This
indicates that amifostine may prevent and reduce the severity of
oral mucositis in adults with head and neck cancer treated with
radiotherapy. This is based on evidence from five trials with 446
participants. In two of the trials the allocation concealment was
adequate, none had a blinded outcome assessment and two had
an adequate explanation of withdrawals, with withdrawals across
the five trials ranging from 0% to 21%.
• Antibiotic pastille or paste versus placebo (MetaView ’Compar-
ison 01’, ’Outcome 01, 02, 03’)
One trial compared antibiotic pastilles with a placebo (Symonds
1996) and one trial antibiotic paste PTA with a placebo (Wijers
2001). For the outcome of mucositis 0 versus 1+ the pooled meta-
analysis for the topical antibiotics was homogeneous and signifi-
cant with mucositis prevented RR = 0.87 (95% CI: 0.79 to 0.97).
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For the other dichotomies there was no evidence that antibiotic
paste was more effective than placebo. This finding indicated that
topical antibiotic may be beneficial at preventing mucositis is based
on evidence from 198 adults treated for head and neck cancer, one
trial was double blind and both trials failed to give clear informa-
tion about allocation concealment.
• Benzydamine versus placebo (MetaView ’Comparison 01’,
’Outcome 01’)
One trial compared benzydamine with a placebo (Prada 1987)
and for the outcome of mucositis 0 versus 1+ there was evidence
that it prevented mucositis compared to placebo RR = 0.67 (95%
CI: 0.47 to 0.97). This finding is based on a single trial of only
36 participants and is therefore considered weak and unreliable
evidence of a benefit.
• Camomile versus placebo (MetaView ’Comparison 01’, ’Out-
come 01, 02, 03’)
One trial compared camomile with a placebo (Fidler 1996). Data
were provided for all three dichotomies of mucositis. No statisti-
cally significant differences were found therefore there is insuffi-
cient evidence to support or refute camomile as more or less effec-
tive than placebo.
• Chlorhexidine versus placebo/no treatment (MetaView ’Com-
parison 01’, ’Outcomes 01, 02, 03’)
Six trials compared chlorhexidine with either a placebo or no treat-
ment control group. All trials provided data on the incidence of
mucositis which could be dichotomised at some level, along the
five point scale (0-4). Four trials (Dodd 1996; Ferretti 1988; Fer-
retti 1990; Foote 1994) provided data for the first dichotomy
(0 versus 1-4), and there was no evidence that the chlorhexidine
mouthrinse was more effective than placebo or no treatment con-
trol in preventing mucositis RR = 0.67 (95% CI: 0.33 to 1.36,
chi squared = 30, df = 4, p < 0.001). Only one trial (Foote 1994)
provided data comparing mucositis dichotomised as 0-1 versus 2+
, and this was not significant, data from this trial failing to show
a benefit for chlorhexidine. Three trials (Foote 1994; Spijkervet
1989; Wahlin 1989) provided data for the third dichotomy of
mucositis 0-2 versus 3+ and once again this was not significant,
with no benefit for chlorhexidine being demonstrated.
• Folinic acid versus no treatment (MetaView ’Comparison 01’,
’Outcome 01, 02, 03’)
One trial compared folinic acid with a no treatment control group
(Erlichman 1988). Participants in the no treatment group were
less likely to experience mucositis compared with those receiving
folinic acid. This difference was statistically significant for the
dichotomies of mucositis 0 versus 1+ RR = 3.65 (95% CI: 2.38
to 5.58) and mucositis 0-1 versus 2+, RR = 2.38 (95% CI: 1.35
to 4.21). This trial was published in 1988 and initially involved
130 patients receiving 5 FU chemotherapy for solid tumours. It
was unclear if the assessor was blinded to the treatment group and
information on withdrawals was not provided. It provides weak
evidence that folinic acid might induce mucositis compared with
no treatment. This would be expected as folinic acid potentiates
5 FU cytotoxic activity.
• Glutamine versus placebo (’Additional Table 02, Table 03 and
Table 04’)
Five trials, two of which had a cross-over design, included the
intervention glutamine compared with placebo (Anderson 1998;
Dickson 2000; Huang 2000; Jebb 1994; Okuno 1999). None
of the meta-analyses found any significant differences between
glutamine and placebo. Two trials provided data for the first di-
chotomy 0 versus 1-4, however as every patient developed mucosi-
tis in one trial (Huang 2000), only the results from the other trial
(Okuno 1999) could be considered. This study did not demon-
strate a benefit for glutamine when compared with placebo. Five
trials (Anderson 1998; Dickson 2000; Huang 2000; Jebb 1994;
Okuno 1999) provided data for the 0-1 versus 2-4 dichotomy and
three of these for the 0-2 versus 3-4 dichotomy. The meta-analy-
ses demonstrated no evidence that glutamine prevented mucositis
formation at any level of severity.
• GM-CSF versus placebo/no treatment (MetaView ’Compari-
son 01’, ’Outcome 01, 02, 03’)
Seven trials compared GM-CSF with a placebo or no treatment
control group. Five trials were placebo (Cartee 1995, Nemunaitis
1995, Van der Leslie 2001) two of which (Crawford 1999, Schnei-
der 1999) compared filgrastim (recombinant human granulocyte-
colony stimulating factor) and two trials had a no treatment con-
trol group (Katano 1995, Makkonen 1994). Three trials provided
data for the dichotomy of mucositis 0 versus 1+ (Crawford 1999;
Katano 1995; Makkonen 1994) the meta-analysis was statistically
significant with evidence that GM-CSF prevents mucositis RR =
0.51 (95% CI: 0.29 to 0.91, chi squared = 1.35, df = 1, p = 0.24).
The data were homogeneous for the two contributing trials be-
cause in one trial every patient developed mucositis (Makkonen
1994). For the other dichotomies there was no evidence that GM-
CSF was more effective than placebo or no treatment. Evidence for
the benefit for GM-CSF is moderate based on two trials with data
from 209 adults treated for solid tumours and in each study it was
unclear if the assessor was blind. The absence of benefit at levels
of mucositis other than absence or presence of mucositis suggests
that it may prevent mucositis rather than reduce its severity.
• Hydrolytic enzymes versus no treatment (MetaView ’Compar-
ison 01’, ’Outcome 01, 02, 03’)
One trial compared hydrolytic enzymes with a no treatment con-
trol group (Gujral 2001) and one compared wobe-mugos with a
no treatment control group (Kaul 1999). Both trials provided data
for each of the meta-analyses. Individually the trials were signifi-
cant for different levels of mucositis. The pooled meta-analysis did
not find a difference for the dichotomy of mucositis absent versus
present, however, significant differences were found for mucositis
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0-1 versus 2+ RR = 0.49 (95% CI: 0.30 to 0.81) and for mucosi-
tis 0-2 versus 3+, RR = 0.18 (95% CI: 0.06 to 0.53). For both
of these comparisons the data were homogeneous, based on 149
adults treated for head and neck cancer in open trials, one with ad-
equate allocation concealment and unclear information on with-
drawals in both. The evidence suggests that hydrolytic enzymes
may reduce the severity of mucositis associated the treatment of
head and neck cancer rather than prevent it.
• Ice chips versus no treatment (’Additional Table 02, Table 03
and Table 04’)
Two trials (Cascinu 1994; Mahood 1991), one of which was de-
signed as a cross-over trial compared ice chips with a no treat-
ment control group. Significant differences were found at the first
two dichotomies of mucositis, with odds ratios of 0.42 (95% CI:
0.19 to 0.93) and 0.36 (95% CI: 0.15 to 0.89) for absent versus
present and 0-1 versus 2+ respectively. The evidence is moderate
from two trials with 166 patients treated with 5 FU chemotherapy.
The quality of the reporting of the trials varied and neither had a
blinded outcome assessment. This indicated that ice chips may be
beneficial in preventing or reducing the severity of mucositis for
patients treated with 5 FU.
• Oral care versus no treatment or limited oral hygiene (MetaView
’Comparison 01’, ’Outcome 01, 02, 03’)
Two trials compared oral care with no treatment or limited oral
hygiene (Borowski 1994, Shieh 1997) and reported outcomes at
different levels of mucositis. A significant difference was found for
oral care versus no treatment (Shieh 1997) at the level of mucositis
0 versus 1+ with a relative risk of 0.60 (95% CI: 0.42 to 0.86). The
other trial did not find a significant difference between intensive
and limited oral hygiene. This indicates that oral care interventions
may be beneficial in preventing mucositis however the evidence is
weak and based on a single study of 30 adults treated for head and
neck cancer with radiotherapy. There was adequate concealment
of allocation, no drop outs and the outcome assessor was blinded
to treatment group.
• Pentoxifyline versus no treatment (MetaView ’Comparison 01’,
’Outcome 02’)
One trial compared pentoxifyline with a no treatment control
group (Attal 1993). Data were provided at the dichotomy of mu-
cositis 0-1 versus 2+. No statistically significant differences were
found therefore there is insufficient evidence to support or refute
that pentoxifyline is more or less effective than no treatment.
• Povidone versus water (MetaView ’Comparison 01’, ’Outcome
01, 02, 03’)
One trial compared povidone with water (Rahn 1997) and for each
dichotomy of mucositis povidone was significantly more effective
than water for mucositis 0 versus 1+, RR = 0.70 (95% CI: 0.53 to
0.93), mucositis 0-1 versus 2+ RR = 0.45 (95% CI: 0.28 to 0.73)
and mucositis 0-2 versus 3+ RR = 0.31 (95% CI: 0.12 to 0.78).
This indicates that povidone may be beneficial at preventing and
reducing the severity of mucositis. The evidence is weak based
on a single study of 40 adults treated for head and neck cancer
with unclear concealment of allocation, no drop outs and blinded
outcome assessment.
• Prednisone versus placebo (MetaView ’Comparison 01’, ’Out-
come 01, 02, 03’)
One trial compared prednisolone with a placebo (Leborgne 1997).
Data were provided at all three dichotomies of mucositis. No sta-
tistically significant differences were found and therefore there is
insufficient evidence to support or refute that prednisone is more
or less effective than placebo.
• Propatheline versus placebo (MetaView ’Comparison 01’, ’Out-
come 01’)
One trial compared propatheline with a placebo (Ahmed 1993).
Data were provided at the dichotomy of mucositis 0 versus 1+. No
statistically significant differences were found and therefore there
is insufficient evidence to support or refute that propatheline is
more or less effective than placebo.
• Prostoglandin versus placebo (MetaView ’Comparison 01’,
’Outcome 01, 03’)
Two trials compared prostoglandin with a placebo (Duenas 1996,
Labar 1993). Data were provided for two of the dichotomies of
mucositis. No statistically significant differences were found and
therefore there is insufficient evidence to support or refute that
prostoglandin is more or less effective than placebo.
• Sucralfate versus placebo (’Additional Table 02, Table 03 and
Table 04’)
Six trials, one of which had a cross-over design (Pfeiffer 1990),
compared the intervention sucralfate with a placebo (Carter 1999;
Cengiz 1999; Franzen 1995; Makkonen 1994; Pfeiffer 1990;
Shenep 1988). Data were provided at three dichotomies of mucosi-
tis. No statistically significant differences were found and therefore
there is insufficient evidence to support or refute that sucralfate is
more or less effective than placebo.
• Systemic antibiotic clarithromycin versus no treatment
(MetaView ’Comparison 01’, ’Outcome 02’)
One trial compared clarithromycin with no treatment (Yuen
2001). Data were provided at the dichotomy of mucositis 0-1 ver-
sus 2+. The difference was on the borderline of statistical signifi-
cance RR = 0.69 (95% CI: 0.48 to 1.01). This indicated that this
systemic antibiotic may reduce the severity of mucositis and the
results may be considered with those of topical antibiotics.
• Traumeel versus placebo (MetaView ’Comparison 01’, ’Out-
come 01’)
One trial compared traumeel with a placebo (Oberbaum 2001).
Data were provided at the dichotomy of mucositis 0 versus 1+. No
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statistically significant difference was found and therefore there is
insufficient evidence to support or refute that traumeel is more or
less effective than placebo.
ADDITIONAL OUTCOMES
The information relating to additional outcomes and side effects
was variable across the 52 included studies. To explore these fur-
ther, for the interventions found to be beneficial at preventing or
reducing the severity of mucositis data were pooled and synthe-
sised for side effects relating to amifostine (Meta-analysis ’Com-
parison 02’ ’Outcome 01’) and GM-CSF (Meta-analysis ’Com-
parison 02’ ’Outcome 02’).
Of the six trials evaluating amifostine four reported seven side ef-
fects (Antonadou 2002; Brizel 2000; Bourhis 2000; Koukourakis
2000). For five of these, data from more than one study were
available. No significant difference was found between amifostine
and no treatment control for survival at 24 months, recurrence at
18 months after cancer treatment, incomplete response to radio-
therapy, hypotension and nausea. Delay to radiotherapy was on
the borderline of significance with those receiving amifostine less
likely to have a delay to receiving radiotherapy for cancer however,
it was based on a single study of 39 patients RR = 0.44 (95% CI:
0.19 to 1.01). The only significant finding was for vomiting with
no patients in the control group compared with 10/182 treated
with amifostine experiencing this side effect RR = 5.92 (95% CI:
1.03 to 33.91, chi squared = 1.01, df = 2, p = 0.6).
Of the seven trials evaluating GM-CSF only two provided useable
data for side effects (Makkonen 2000; Nemunaitis 1995) and not
the same side effect. No difference was found between patients
receiving GM-CSF and no treatment control for survival at 24
months, survival at 12 months, relapse within 1 year or nausea.
A significant difference was found for local skin reactions with
patients receiving GM-CSF more likely to experience a rash RR =
27 (95% CI: 1.71 to 425).
NUMBER NEEDED TO TREAT
Numbers needed to treat (NNTs) have only been calculated for
interventions with more than one study reporting mucositis at the
level of absence versus present. The NNT to prevent one patient
experiencing mucositis over a baseline incidence of 60% for ami-
fostine is 33 (95% CI: 20 to 100), antibiotic paste or pastille 13
(95% CI: 8 to 50), GM-CSF 3 (95% CI: 2 to 20) and ice chips 5
(95% CI: 2 to 31). When baseline incidence is 40% or 90% the
NNTs for amifostine are 50 and 20, for antibiotic paste or pastille
20 and 8, for GM-CSF 5 and 2 and for ice chips 6 and 10.
D I S C U S S I O N
This review updates the evidence for interventions for the pre-
vention of oral mucositis for patients receiving cancer treatment
and includes considerably more evidence than the initial review
(Clarkson 2003a). This is due to the inclusion of interventions for
patients with head and neck cancer and the expansion of evidence
in this area of cancer care. Oral mucositis is a common complica-
tion of cancer chemotherapy and radiotherapy causing severe pain
and may limit the tolerability to chemotherapy and radiotherapy
and consequently the effectiveness of treatment (Kowanko 1998).
The findings of this review should be considered in context with
the general medical management of patients with cancer. Outcome
measures, other than clinical scores for mucositis, were predom-
inantly reported in recent publications. Rarely did they consider
clinically meaningful outcomes such as oral pain, use of opiod anal-
gesic, oral intake, quality of life, duration of hospital stay (Bellm
2002).
The number and range of interventions included in this review in-
dicates the uncertainty and importance of this clinical topic. The
52 trials included in this review have evaluated 21 interventions
and recruited 3594 patients. The country of conduct, financial
support and the design of trials have varied. Surprisingly despite
the common recruitment of patients into multicentre cancer treat-
ment trials the same has not happened for their oral care. The two
multicentre trials were the largest with respect to patient recruit-
ment. The lack of duplication of studies investigating the same
interventions limits the strength of evidence and generalisability.
The eligible trials for this review varied in their design and quality
and it was especially unfortunate that 34 studies presented data
in an unusable form. We feel that the use of structured abstracts
and adherence to the CONSORT guidelines will greatly improve
the reporting and hopefully the conduct of randomised controlled
trials (RCTs) (Begg 1996; Moher 2001). With respect to publica-
tion bias, several negative studies for mucositis have been reported
and we congratulate the authors and editors for doing so. It was
not possible to detect any existing publication bias, as there were
insufficient studies in each meta-analysis investigating the same
interventions.
The setting of the included trials varied with the majority being
conducted by medical teams who did not report any involvement
with a dentist (73%). An issue that was not considered in any of
the trials was the reliability and validity of the outcome measures
assessed. The appearance of the mucositis and oral candidiasis can
be similar; therefore if the assessor is neither trained nor expe-
rienced in the diagnosis of these oral lesions, the validity might
be affected. Scores of mucositis were not always defined although
there was consistency in the number of categories of the indices
used, with the lowest indicating no mucositis.
The reporting of outcomes other than mucositis was variable and
they were reported more frequently in trials published within the
last 5 years than before. The type of outcomes reported has changed
to reflect more the characteristics identified as clinically meaning-
ful and important to patients (Bellm 2002). Only interventions
to prevent mucositis were included in this review however using a
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range of dichotomies for mucositis the findings can be interpreted
also as reduction in severity.
Nine of the 21 interventions were found to have some evidence
of a benefit (albeit sometimes weak) in preventing or reducing the
severity of mucositis. One intervention, folinic acid, was signif-
icantly worse than placebo. A summary of the nine potentially
effective interventions is given below:
• Allopurinal is a xanthine-oxidase inhibitor thought to reduce
the mucosal toxicity of chemotherapy drugs. The evidence for
its use as a mouthwash is a significant odds ratio of approxi-
mately zero (95% confidence interval (CI): 0, 0.03) only for a
reduction in severe mucositis (Grades 0-2 versus 3) whilst this-
appears to be a strong finding it is possibly unreliable as it is
based on two small trials.
• Amifostine is an aminothiol free radical scavenger. It appears to
have small benefit in preventing relative risk (RR) = 0.95 (95%
CI: 0.91to 0.99) and reducing the severity of mild mucositis RR
= 0.83 (95% CI: 0.72 to 0.97). This is based on the largest body
of evidence found in this review, from five trials with 446 par-
ticipants. The side effects of amifostine were not significantly
different to no treatment for survival at 24 months, recurrence
at 18 months after cancer treatment, incomplete response to
radiotherapy, hypotension and nausea. Delay to radiotherapy
was on the borderline of significance with those receiving am-
ifostine less likely to experience a delay RR = 0.44 (95% CI:
0.19 to 1.01). The only significant finding was for vomiting
with no patients in the control group compared with 10/182
treated with amifostine experiencing this side effect RR = 5.92
(95% CI: 1.03 to 33.91).
• Antibiotic as a topical pastille or paste may be beneficial at
preventing mucositis RR = 0.87 (95% CI: 0.79 to 0.97) based
on two trials with evidence from 198 adults treated for head
and neck cancer. The borderline significant result for systemic
antibiotics reinforces the potential of antibiotics having some
mild benefit.
• Benzydamine, an indirect cytoprotectant, was compared to
placebo in one trial and was found to be significantly more ef-
fective for preventing mucositis RR = 0.67 (95% CI: 0.47 to
0.97). The evidence is weak based on one trial of 36 adult pa-
tients with head and neck cancer.
• GM-CSF and related products are cytokines which stimulate
haemopoesis and modulate leukocyte functions. Three trials
provided evidence that GM-CSF prevents mucositis RR = 0.51
(95% CI: 0.29 to 0.91) and these data were from 249 adults
treated for solid tumours. In the absence of evidence for ben-
efit at other levels of mucositis it suggests that GM-CSF may
prevent mucositis rather than reduce its severity. Two trials pro-
vided useable data for side effects and no difference was found
between patients receiving GM-CSF and no treatment control
for survival at 24 months, survival at 12 months, relapse within
1 year or nausea. A significant difference was found for local
skin reactions with patients receiving GM-CSF more likely to
experience a rash RR = 27 (95% CI: 1.71 to 425).
• Hydrolytic enzymes have analgesic and anti-inflammatory
properties. Two trials provided evidence of moderate benefit at
reducing the severity if mucositis rather than preventing it with
mucositis 0-1 versus 2+ RR = 0.49 (95% CI: 0.30 to 0.81) and
mucositis 0-2 versus 3+ RR = 0.18 (95% CI: 0.06 to 0.53). For
both of these comparisons the data were homogeneous, based
on 149 adults treated for head and neck cancer in open trials.
• Ice chips are thought to act by producing local vasoconstriction
therefore limiting the cytotoxic effects of chemotherapy. The
evidence is moderate from two trials with 166 patients treated
with 5 FU chemotherapy. Significant differences were found at
two dichotomies of mucositis, with odds ratios of 0.42 (95%
CI: 0.19 to 0.93) and 0.36 (95% CI: 0.15 to 0.89) for absent
versus present and 0-1 versus 2+ respectively.
• Povidone was compared to water in only one trial and for each
dichotomy of mucositis povidone was significantly more effec-
tive than water with RRs 0.70 (95% CI: 0.53 to 0.93), 0.45
(95% CI: 0.28 to 0.73) and 0.31 (95% CI: 0.12 to 0.78) re-
spectively. The evidence is weak based on a single study of 40
adults treated for head and neck cancer.
• Oral care is compared with no treatment in two trials, however
only one trial found a significant difference for oral care versus
no treatment at the level of mucositis 0 versus 1+ with a relative
risk of 0.60 (95% CI: 0.42 to 0.86). The evidence that oral
care interventions may be beneficial in preventing mucositis is
weak, based on a single study of 30 adults treated for head and
neck cancer with radiotherapy.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Several of the interventions were found to have some benefit at
preventing or reducing the severity of mucositis associated with
cancer treatment. The strength of the evidence was variable and
implications for practice include consideration of the fact that
benefits may be specific for certain cancer types and treatment.
Implications for research
There is a need for well designed and conducted trials with suf-
ficient numbers of participants to perform subgroup analyses by
type of disease and chemotherapeutic agent. This review has high-
lighted several interventions for which further research into the
benefits and harms should be conducted. There should be con-
tinued evaluation of agents for mucositis. Outcome measures of
any future trial should address the link between oral and general
health including the outcomes relevant to the patient and as a
11Interventions for preventing oral mucositis for patients with cancer receiving treatment (Review)
Copyright © 2006 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd
minimum they should include the reduction of oral pain, the use
of opiod analgesics, improvement in oral intake and quality of life,
and reduction of hospitalisation duration. Collaboration between
medical and dental teams is indicated with a consensus on the
choice of objective oral indices for mucositis.
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with cancer treated with chemotherapy (excluding head and neck
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T A B L E S
Characteristics of included studies
Study Ahmed 1993
Methods Randomised, parallel group study conducted in USA. Patients, providers and assessors blind. Clear informa-
tion on withdrawals: none. Dentist not involved in study. Drop outs: 0%. Duration: return of blood count
or resolution of mucosistis.
Participants Adults with haematological malignancies prior to BMT after conditioning with etoposide. 12 enrolled and
completed.
Interventions 2 groups, placebo versus propantheline (30 mg every 6 hours during infusion and 12 hours after, for total of
6 doses).
Outcomes Mucositis graded with reference to previous publication. Data presented as number of patients developing
mucositis in both groups. Assessment used: day 3. Other reported outcomes: blood counts febrile episodes,
survival, tumour response.
Notes All patients received acyclovir, and nystatin or clotrimazole.
Funding source: unclear.
Allocation concealment B
Study Anderson 1998
Methods Randomised, cross-over study conducted in USA. Patients, providers and assessors blind. Clear information
on withdrawals. Dentist not involved in study. Drop outs: 46%. Duration 14 days.
Participants Children and adults with solid cancer who have previously had chemotherapy and experienced mucositis.
24 patients eligible and enrolled, 13 completed.
Interventions 2 groups, glycine control (described as placebo) versus glutamine (4 ml/M² twice daily swish and swallow).
Outcomes Mucositis (patient’s description on 0-4 scale). Grade >= 2 painful mucositis which altered food intake.
Assessment used: day 14. Other reported outcomes: none.
Notes Funding source: private.
Allocation concealment B
Study Antonadou 2002
Methods Randomised, parallel group study conducted in Greece. Patients, providers and assessors not blind. Clear
information on withdrawals: 3/26 control, 2/24 test. Dentist not involved in study. Drop outs: 10%. Duration
3 months.
Participants Adults with head and neck cancer. Radiotherapy total 60-74 Gy 2 Gy fractions 5 days weekly. Chemotherapy
carboplatin (90 mg/m2 once per week (no surgery before radiotherapy). 50 patients enrolled, 45 completed.
Interventions 2 groups, no treatment control versus amifostine 300 mg/m2 15-30 min before radiotherapy for 6-7 weeks.
Outcomes Mucositis assessed weekly EORTC criteria. Assessment used: day 28. Other reported outcomes: dysphagia,
xerostomia, treatment interruptions, haematological changes, side effects (nausea, transient hypotention).
Notes Funding source: unclear.
Allocation concealment B
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Characteristics of included studies (Continued )
Study Attal 1993
Methods Randomised, parallel group study conducted in France. Patient and providers not blind, unclear whether
assessor blind. Clear information on withdrawals: 6/70 control, 6/70 test. Dentist not involved in study.
Drop outs: 0%. Duration: day -8 to day +100.
Participants Adults with blood cancer admitted to BMT unit. 140 patients enrolled 6 died in each group, but all were
evaluated.
Interventions 2 groups, no treatment control versus pentoxifylline (oral PTX 1600 mg 1 per day in 4 doses).
Outcomes Number requiring MSO4 for grade II or higher mucositis (by published criteria). Assessment used: day 100.
Other reported outcomes: duration of stay in hospital, renal insufficiency, days morphine, fever, septicaemia,
100 day survival.
Notes All patients received fluconazole, acyclovir and ranitidine.
Funding source: unclear.
Allocation concealment A
Study Borowski 1994
Methods Randomised, parallel group study conducted in France. Patient, providers and assessors not blind. Clear
information on withdrawals: 7/82 control, 9/84 test. Dentist involved in study. Drop outs: 7%. Duration:
30 days.
Participants Children and adults with blood cancer and candidates for BMT. 166 eligible and enrolled, 150 completing.
Interventions 2 groups, limited oral hygiene versus intense oral hygiene (brushing 3 times per day after meals as instructed
by dentist).
Outcomes Moderate or severe mucositis with detailed description of each category. Assessment used: day 30. Other
outcomes: plaque, fever, septicaemia.
Notes Chlorhexidine mouthrinse used at least 5 times daily by both groups.
Funding source: unclear.
Allocation concealment A
Study Bourhis 2000
Methods Randomised, parallel group study conducted in France. Patients and providers not blind, unclear whether
assessors blind. Unclear information on withdrawals: 1 died and 1 refused, unclear which group. Dentist not
involved in study. Drop outs: 8%. Duration: unclear.
Participants Adults with head and neck cancer, stage IV not amenable to conventional radiosurgical treatment. Karnofsky
performance > 60. Radiotherapy 64 Gy in 22-23 days. 26 patients enrolled, 24 were evaluated.
Interventions 2 groups, no treatment control versus amifostine (subcutaneous infusion 150 mg/m² amifostine administered
IV twice daily 15-30 mins prior to each radiotherapy session).
Outcomes Max WHO grade (I to IV). Assessment used: day 23. Other reported outcomes: duration of feeding tube,
vomiting, liver function, erythaema (tolerance of amifostine). Duration of feeding tube.
Notes RTOG index also given with mean duration of at least grade 3 mucositis.
Funding source: pharmaceutical.
Allocation concealment A
Study Brizel 2000
Methods Randomised, parallel group study conducted as multicentre USA, Germany and France. Patients, providers
and assessors blind. Clear information about withdrawals: none. Drop outs: 0%.
Duration: 1 year.
20Interventions for preventing oral mucositis for patients with cancer receiving treatment (Review)
Copyright © 2006 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd
Characteristics of included studies (Continued )
Participants Adults with head and neck cancer. Newly diagnosed squamous cell radiation more than or equal to 70%
both parotid glands more tahn or equal to 40 Gy - daily 2 Gy.
Interventions 2 groups, no treatment control versus amifostine 200 mg/m2 daily 15-20 minutes prior to radiation.
Outcomes Mucositis assessed weekly by physician. Radiation Therapy Oncology Group Scoring systems. Assessment
used: day 90. Other reported outcomes: nausea, vomiting, xerostomia, saliva production, survival, local
disease control.
Notes Funding Source: pharmaceutical.
Allocation concealment A
Study Bubley 1989
Methods Randomised, parallel group study conducted in USA. Patients, providers and assessors blind. Unclear infor-
mation on withdrawals. Dentist not involved in study. Drop outs: unclear. Duration: unclear.
Participants Adults with head and neck cancer. Prior positive titre to Herpes Simplex.
Interventions 2 groups, placebo versus acyclovir 200 mg tablets 12 hourly.
Outcomes Mucositis assesed by nurse. Assessment used: unclear. Other reported outcomes: herpes simplex virus.
Notes Data presented separately for patients receiving chemo and radiotherapy.
Funding source: pharmaceutical.
Allocation concealment A
Study Buntzel 1998
Methods Randomised, parallel group study conducted in Germany. Patient and providers not blind, unclear if assessors
blind. Clear information on withdrawals: none. Dentist not involved in study. Drop outs: 0%. Duration: 6
weeks.
Participants Adults with head and neck cancer, hospitalised with stage III-IV tumour, no evidence of systemic infection,
liver or renal impairment, tumour resected or excised before adjuvant radiotherapy. 28 patients enrolled, 28
were evaluated.
Interventions 2 groups, radiotherapy with or without amfostine (15 min infusion 500 mg preceded by antiemetic regime
of 12 mg dexamethasone and 8 mg ondansetron).
Outcomes WHO mucositis grades 3/4. Assessment used: day 42. Other reported outcomes: xerostomia, dysphagia, loss
of taste, dermatitis, haematological side effects.
Notes More data presented but included extra 11 patients in amifostine group who were not entered into study.
Funding source: pharmaceutical.
Allocation concealment B
Study Cartee 1995
Methods Randomised, parallel group study conducted in USA. Patient, provider and assessor blind. Unclear informa-
tion on withdrawals: 5 withdrew, unclear from which groups. Dentist involved in study. Drop outs: 10%.
Duration: 21 days.
Participants Adults with breast cancer stage IV, with combination of chemotherapy including 5-FU, Adriamycin &
methotrexate. First cycle of chemotherapy. 50 patients were enrolled and 45 were evaluated.
Interventions 5 groups, 0.1% albumin (described as placebo, dose 0), GM-CSF (molgramostim, range of doses, 0.01, 0.10,
1.00, 10.00 mcg/ml. Mouthwash solutions administered 4 times daily starting 24 hours after chemotherapy
initiation). continuing until end of cycle.
Outcomes Mucositis (CALGB GRADE >= 3). Assessment used: day 15. Other reported outcomes: WBC, plasma GM-
CSF.
Notes Doses 0.01, 0.10, 1.00, 10.00 were combined and compared with dose 0 (control).
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Characteristics of included studies (Continued )
Funding source: government.
Allocation concealment A
Study Carter 1999
Methods Randomised, parallel group study conducted in USA. Patient, provider and assessor blind. Clear information
on withdrawals: none. Dentist not involved in study. Drop outs: 0%. Duration: up to 4 months postradio-
therapy.
Participants Adults with head and neck cancer receiving curative intent radiotherapy, karnofsky performance > 60. 102
patients enrolled and 102 completed.
Interventions 2 groups, placebo versus sucralfate (added as suspension of 1 gm sucralfate/15 ml solution) swish 2 mins and
swallow 4 times per day.
Outcomes RTOG graded mucositis. Assessment used: maximum during treatment at 60 Gy. Other reported outcomes:
pain, need for placement of feeding tube, use of narcotics, need for intravenuous fluids, diet, need for
treatment break. All assessed weekly.
Notes Funding source: unclear.
Allocation concealment B
Study Cascinu 1994
Methods Randomised, parallel group study conducted in Italy. Patient, provider and assessor not blind (c). Clear
information on withdrawals: none. Dentist not involved in study. Drop outs: 0%. Duration: unclear.
Participants Adults with solid cancer (GI & prostate). Chemotherapy: 5-FU flurouracil. First course of chemotherapy.
84 patients eligible, enrolled and completed.
Interventions 2 groups, control (no treatment) versus ice chips (cryotherapy, 5 mins before 5-FU for 30 mins after).
Checked every week and judgement on mucositis performed on day of next chemotherapy course.
Outcomes Mucositis (Global assessment of physician’s and patient’s description on 0-4 scale). Assessment used: unclear.
Notes Statistical handling of data incorrect as all cycles included but used data from first cycle.
Funding source: unclear.
Allocation concealment A
Study Cengiz 1999
Methods Randomised, parallel group study conducted in Turkey. Patient and provider blind unclear if assessor blind.
Clear information on withdrawals: none. Dentist not involved in study. Drop outs: 0%. Duration from
beginning to end of radiotherapy.
Participants Adults with head and neck cancer. 28 patients enrolled and completed.
Interventions 2 groups, placebo versus sucralfate (6 g sucralfate suspension mouthwash 4 doses orally before meals and
bedtime).
Outcomes RTOG mucositis (0-IV). Topical and systemic analgestic use, weight loss, dry mouth. Assessment used: day
42. Other reported outcomes: pain, difficulty eating, constipation, analgesics, dry mouth.
Notes Funding source: unclear.
Allocation concealment B
Study Crawford 1999
Methods Randomised, parallel group study conducted in USA. Patient blind, unclear whether assessor and provider
was. Unclear information on withdrawals (previously described): 6/110 placebo, 6/101 test. Dentist not
involved in study. Drop outs: 9%. Duration: from day 4 to day 17 of cycle.
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Characteristics of included studies (Continued )
Participants Adults with small cell lung cancer. 211 patients enrolled, 199 evaluated, 195 evaluated on first cycle.
Interventions 2 groups: placebo (not described) versus filgrastim (230 ug/m²).
Outcomes WHO mucositis grades 0-4. Assessment used: day 21. Other reported outcomes: neutropenia, infections
complications.
Notes Used first cycle data.
Funding source: unclear.
Allocation concealment B
Study Dickson 2000
Methods Randomised, parallel group study conducted in USA. Patient not blind (c), assessor blind and unclear
whether provider was. Clear information on withdrawals: none. Dentist not involved in study. Drop outs:
0%. Duration: first day of treatment until discharge or max 28 days after transplant.
Participants Adults receiving bone marrow transplant (BMT). 58 enrolled and evaluated with haematological and solid
cancer.
Interventions 2 groups, sugar water (placebo) versus glutamine (30 g in 10 g doses mixed with food or liquid chosen by
patient).
Outcomes Stamford University Hospital BMT toxicity scale for mucositis scale 0-4. Reported as grade 2+. Parenteral
nutrition with TPN. Assessment used: day 28. Other reported outcomes: length of hospital stay. Days in
total, parenteral nutrition, diarrohea, toxicity.
Notes Funding source: pharmaceutical supply product.
Allocation concealment B
Study Dodd 1996
Methods Randomised, parallel group study conducted in USA. Patient not blind (c), providers and examiners were
blind. Clear information on withdrawals: none. Dentist involved in study.
Dop outs: 0%. Duration: up to 3 months.
Participants Adults with solid cancer receiving chemotherapy. Followed for 3 cycles of chemotherapy. 303 eligible, 227
enrolled and evaluated.
Interventions 2 groups: water control (described as placebo) versus chlorhexidine mouthrinse (0.12%, 20 ml, 2 times per
day).
Outcomes Oral Assessment Guide (OAG) 0-24, scores over 10 were considered to be oral mucositis. Maximum of 3
months. Assessment used: day 90. Other reported outcomes: cost.
Notes Severity of mucositis at onset measured. Intent to treat analysis.
Funding source: government.
Allocation concealment A
Study Dozono 1989
Methods Randomised, cross-over study conducted in Japan. Patients and providers were not blind, it is unclear if
assessor was. Clear information on withdrawals: none. Unclear if dentist was involved. Drop outs: 0%.
Duration: unclear.
Participants Adults with solid cancer receiving chemotherapy. 15 patients enrolled and completed both periods.
Interventions 2 groups: no treatment control versus allopurinol mouthwash (carboxymethylcellulose (CMC-Na) 5 g and
allopurinol 500 mg, water to 500 ml solution).
Outcomes Japan Society for Cancer Therapy criteria for stomatitis 0-4 scale.
Notes Funding source: unclear.
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Allocation concealment A
Study Duenas 1996
Methods Randomised, parallel group study conducted in Mexico. Patients, providers and assessors were blind. Clear
information on withdrawals: none. Unclear if dentist was involved in study.
Drop outs: 0%. Duration: -4 to day 16.
Participants Adults with mixed cancer undergoing peripheral stem cell transplant, receiving high dose (ifosfamide, car-
biplatin, etoposide). 15 patients enrolled (16 course of chemotherapy).
Interventions 2 groups, placebo versus misoprostol (racemic prostaglandin E1 analogue) 250 ug 3 times per day.
Outcomes WHO mucositis grades 0-4, candidiasis, days in hospital with range. Assessment used: day 16.
Other reported outcomes:
diarrohea, fever, days in hospital, duration of antibiotics.
Notes All patients received fluconazole prophylaxis. Also received ranitidine, ketoconazole & ciprofloxacin. Severity
of mucositis also given but no SD. Study stopped prematurely due to a significant finding at an interim
analysis, favouring the placebo.
Funding source: government, pharmaceutical.
Allocation concealment A
Study Erlichman 1988
Methods Randomised, parallel group study conducted in Canada. Patients and providers not blind, unclear whether
assessor blind. Unclear information on withdrawals. Dentist not involved in study. Drop outs: 4%. Duration:
unclear.
Participants Adults with solid cancer - recurrent colorectal metastatic. Chemotherapy 5 FU.
Interventions 2 groups, no treatment control versus folic acid 200 mg/m2/d 5 consecutive days before 5 FU. 206 eligible,
130 enrolled, 165 completed.
Outcomes Mucositis (clinical 0-3 scale). Assessment used: day 28. Other reported outcomes: GI toxicity grades.
Notes Funding source: pharmaceutical.
Allocation concealment B
Study Ferretti 1988
Methods Randomised, parallel group study conducted in USA. Patient, providers and assessors were blind. Unclear
information on withdrawals: 1/28 control, 4/28 test. Dentist involved in study. Drop outs: 10%. Duration:
up to 90 days.
Participants Children and adults (1-51 years) with mixed blood haematological and solid cancers receiving BMT. 56
patients enrolled and 51 completed.
Data used n=41.
Interventions 2 groups, placebo versus chlorhexidine gluconate mouthrinse (15 cc 0.12%, 3 times per day for 30s).
Outcomes Mucositis (clinical scale 0-3, but then dichotomised and measured at 7, 14, 25, 33, 60 & 90 days). Assess-
ment used: day 33. Other reported outcomes: gross candida (clinical appearance + swab culture or KOH
preparation), oral streptococus, yeast, gram -ve bacilli, death, morphine use.
Notes Candidemia (persistant candidiasis) also recorded, with 3 deaths due to candida in the control group. Mean
mucositis scores given graphically with bars for SE. Given oral nystatin suspension 15 ml 4 times daily or
clotrimazole troches . Supplemental nystatin soaks or popsicles were used liberally.
Funding source: pharmaceutical.
Allocation concealment A
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Study Ferretti 1990
Methods Randomised, parallel group study conducted in USA. Patient, providers and assessors were blind. Unclear
information on withdrawals: 18/46 control, 15/46 test. Dentist involved in study.
Drop outs: 36%. Duration: 28 days.
Participants Children and adults (1-70 years) with mixed blood and solid cancer. High dose chemotherapy or head and
neck radiation (data separate). 92 enrolled, 59 completed.
Interventions 2 groups, placebo versus chlorhexidine 0.12% ml 3 times/day.
Outcomes Mucositis (scale where 0 = no ulceration)
Assessment used: day 28+. Other reported outcomes: oral micr-strep, yeast, gram-ve bacilli. Systematic
infection measured at day 7, 14, 21, 28.
Notes Mucositis severity given with no s.d. Both groups had some mucositis at baseline.
Funding source: pharmaceutical.
Allocation concealment A
Study Fidler 1996
Methods Randomised, parallel group study conducted in USA. Patient, providers and assessors were blind. Unclear
information on withdrawals: 1/165 total. Dentist not involved in study. Drop outs: 1%. Duration: 14 days.
Participants Adults, cancer type not given. Chemotherapy: first course 5-FU based. 165 enrolled, 164 clinical evaluation,
135 patient evaluation.
Interventions 2 groups, placebo versus camomile (30 drops in 100 ml water, 3 times per day).
Outcomes Mucositis (physician and patient scales 0-4). Score judged historically 4-5 weeks after chemotherapy cycle
initiation. Additionally patient form filled out on daily basis for first 3 weeks after first day of chemotherapy.
Assessment used: day 21. Other reported outcomes: toxicity.
Notes Mean daily mucositis scores shown graphically but no s.d. All patients used ice chips 5 mins before chemo-
therapy and for 30 minutes in total.
Patient’s mucositis scores used.
Funding source: government.
Allocation concealment B
Study Foote 1994
Methods Randomised, parallel group study conducted in USA and Canada. Patient, providers and assessors were blind.
Clear information on withdrawals: none. Unclear if dentist involved in study. Drop outs: 0%. Duration: 14
days.
Participants Adults with head and neck cancer. 52 patients were eligible, enrolled and evaluated.
Interventions 2 groups, placebo versus chlorhexidine (15 ml 4 times per day for 130s).
Outcomes Mucositis scale 0-4 by patient and clinician at weekly intervals. Assessment used: day unclear.
Notes Funding source: pharmaceutical and government.
Allocation concealment A
Study Franzen 1995
Methods Randomised, parallel group study conducted in Sweden. Patient, providers and assessors were blind. Statis-
tician blind. Unclear information on withdrawals: 2/50 total. Unclear if dentist involved in study.
Drop outs: 10%. Duration: -2 to 14 weeks.
Participants Adults with head and neck cancer. 50 patients were enrolled and 48 evaluated.
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Interventions 2 groups, placebo versus sucralfate (granules of sucralfate an alkaline aluminimum hydroxide of suphated
sucrose, swish with 1 dose package 1 g dissolved in water 6 times/day).
Outcomes Patient based assessment of mucositis on 0-3 scale, number with grades 2 or 3 reported. Assessement used:
day 28. Other reported outcomes: mucosal reaction, pain, functional impairment.
Notes Funding source: charity.
Allocation concealment A
Study Gujral 2001
Methods Randomised, parallel group study conducted in India. Patients, providers and assessors nor blind. Unclear
information about withdrawals. Dentist no involved in study. Drop outs: 1%. Duration: 6 months.
Participants Adults with head and neck cancer. T3 and T4 squamous cell cancer, 100 enrolled, 99 evaluated.
Interventions 2 groups, no treatment versus hydrolytic enzymes, papain 100 mg, trypsin 40 mg and chymotrypsin 40 mg.
3 tablets 3 times a day - 3 until + 5.
Outcomes RTOG/EORTE scoring. Assessment used: day 54. Othe reported outcomes: dysphagia, dermatitis.
Notes No oral care except toothbrushing. Funding source: pharmaceutical.
Allocation concealment A
Study Huang 2000
Methods Randomised, parallel group study conducted in Taiwan. Unclear whether patient, providers and assessors
were blind. Clear information about withdrawals (c): none. Dentist not involved in study. Drop outs: 0%.
Duration: beginning of radiation treatment until 25 factions (5 weeks).
Participants Adults with head and neck cancer. 17 patients were evaluated.
Interventions 2 groups, placebo (30 ml saline) versus glutamine (2 g in 30 ml saline, swish 30 ml 3 mins exporate).
Outcomes Clinicians assessed subjective mucositis on 0-4 scale and objective RTOG/EORTC 0-4 scale. WHO step of
analgesic drugs. Assessment used: day unclear.
Notes Subjective mucositis scale used. Funding source: none.
Allocation concealment B
Study Jebb 1994
Methods Randomised, cross-over study conducted in UK. Patient, providers and assessors were blind. Unclear infor-
mation about withdrawals: 11/28 in total. Dentist not involved in study.
Drop outs: 39%. Duration: (1st part) 8 days.
Participants Adults with gastrointestinal cancer undergoing 5-FU & folic acid daily for 5 days and repeated 4 weeks from
start. 28 patients enrolled and 17 completed 2 cycles.
Interventions 2 groups, glucose polymer (Polycal) (described as placebo) versus glutamine (16 gm daily divided into 4
equal doses and dissolved in 150 ml water before consumption).
Outcomes WHO mucositis score, mouth comfort, ease of eating. Assessment used: day 8.
Notes Funding source: none.
Allocation concealment A
Study Katano 1995
Methods Randomised, parallel group study conducted in Japan. Patients, providers and assessors were not blind
(c). Clear information about withdrawals: none. Dentist not involved in study. Drop outs: 0%. Duration:
administration ceased when leukocyte exceeded 8,000/mm³.
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Participants Adults with solid (breast cancer). 14 patients enrolled and evaluated.
Interventions 2 groups, no treatment versus G-CSF (granulocyte colony-stimulating factor, by injection 125 ug).
Outcomes WHO mucositis score (0-4) by clinician. Other reported outcomes: alopecia, fever. Assessment used: day 8.
Notes Funding source: pharmaceutical supply product.
Allocation concealment B
Study Kaul 1999
Methods Randomised, parallel group study conducted in India. Patient, provider and assessor not blind. Unclear
information about withdrawals. Dentist not involved in study. Drop outs unclear. Duration unclear.
Participants Adults with head and neck cancer radiotherapy 50-60 Gy/5-6 weeks. 50 patients enrolled.
Interventions 2 groups, no treatment control versus wobe-mugos enzyme preparation 3 tablets/day 3 days prior to RT
until 1 week after.
Outcomes Mucositis. Assessment used: day 28. Other reported outcomes: xerostomia, skin changes, dysphagia, hospi-
talisation.
Notes Funding source: none.
Allocation concealment B
Study Koukourakis 2000
Methods Randomised, parallel group study conducted in Greece. Patient, provider and assessor not blind. Unclear
information on withdrawals 0/20 control, 1/20 test. Dentist not involved in study. Drop outs: 3%. Duration
6-7 weeks.
Participants Adults with head and neck cancer RT postoperative or inperable dose 64-70 Gy. 40 patients enrolled, 39
completed.
Interventions 2 groups, no treatment control versus amifostine 500 mg daily before RT.
Outcomes Mucositis 0-4 scale combined categories. Assessment used: unclear. Other reported outcomes RT delay, side
effects.
Notes Patients selected from other types of cancer because mucositis data available. Funding source: government
& pharmaceutical.
Allocation concealment B
Study Labar 1993
Methods Randomised, parallel group study conducted in Croatia. Patients and assessors blind but unclear if providers
were. Clear information about withdrawals: none. Dentist not involved in study. Drop outs: 0%. Duration:
+7 to day +21.
Participants Children and adults (5-43 years) with blood and solid cancers, undergoing BMT. 60 patients eligible, enrolled
and evaluated.
Interventions 2 groups, placebo versus prostaglandin E2 (0.5 mg 3 times per day)
Outcomes Clinical and culture fungal measurement. Mucositis (WHO scale for 0-II vs III+, and 0 vs 1+). Severity
over -7 to +35 days. Severity of mucositis also measured but no s.d. given. Assessment used: day 35. Other
reported outcomes: HSV infection, microbiology, vomiting, diarrhoea, fever, death, GVHD (c).
Notes Funding source: none.
Allocation concealment B
Study Leborgne 1997
Methods Randomised, parallel group study conducted in Uruguay (c). Patient, provider and assessor blind. Unclear
information about withdrawals. Dentist not involved in study. Drop out: 4%. Duration 90 days.
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Participants Adults with head and neck cancer radical RT. 69 enrolled, 66 completed.
Interventions 2 groups, placebo versus prednisone 40 mg once daily through day 28 reduced dose to day 43.
Outcomes Mucosistis WHO. Assessment used: unclear. Other reported outcomes: treatment interruptions.
Notes Funding source: none.
Allocation concealment B
Study Loprinzi 1990
Methods Randomised cross-over trial conducted in USA. Patients, providers and assessors were blind. Clear informa-
tion on withdrawals: none. Dentist was not involved. Drop outs: 0%. Duration: 5 days.
Participants Adults with colorectal cancer receiving first 5 day course of 5-FU. 77 patients enrolled, and completed 1st
period, only 20 completed 2nd period.
Interventions 2 groups, placebo versus allupurinol mouthrinse 1 mg/ml made from 450 mg + 150 ml cologel (450 mg/5 mg
methylcellulose with 5% alcohol) +450 ml flavouring agent. 20 ml used for 30s immediately after treatment
then at 1, 2, 3 hours).
Outcomes Mucositis (physician and patient scales 0-4). Assessed used: day 30.
Notes Data cross-tabulated in a form suitable for meta-analysis provided by authors.
Funding source: none.
Allocation concealment A
Study Mahood 1991
Methods Randomised, cross-over study conducted in USA. Patients, providers and assessors not blind. Unclear in-
formation on withdrawals: 2/45 control, 0/50 treatment in first cycle. Dentists not involved in study. Drop
outs 2%. Duration from 5 mins before 5-FU and for 30 mins after.
Participants Unclear age group and cancer type. Chemotherapy first 5 day course of 5-FU. 95 patients eligible and enrolled
and 93 completed first cycle, however, only 82 patients assessed mucositis.
Interventions 2 groups, no treatment control versus ice chips (cryotherapy) placed in the mouth 5 mins before each dose
of 5 FU and replenished over 30 mins.
Outcomes Mucositis (physician & patients scales 0-4) and historical 1 month after treatment. Assessment used: day 28.
Notes Data cross-tabulated in a form suitable for meta-analysis provided by authors.
Funding source: government.
Allocation concealment D
Study Makkonen 1994
Methods Randomised, parallel group study conducted in Finland. Patients blind but unclear if providers and assessors
were. Clear information about withdrawals: none mentioned. Dentist involved in study. Drop outs: 0%.
Duration: during therapy (9 wks).
Participants Adults with head and neck cancer. 40 patients eligible, enrolled and evaluated.
Interventions 2 groups, placebo versus sucralfate (suspension 1 g 6 times per day orally, patients mix granules with 100 ml
water rinse for 1 min then swallow). Rinsed throughout radiotherapy, dose 45-73 Gy.
Outcomes Mucositis on scale 0-2 (0 = no mucositis, 1 = moderate, 2 = severe), at 9 weekly evaluation visits. Assessment
used: day 28. Other reported outcomes: salivary lactoferrin, salivary albumin, amount of anesthetic mouth-
wash, radiotherapy interrupted, toxicity.
Notes Visit at week 4 taken. Antifungal agents given to 29 patients during study.
Funding source: government.
Allocation concealment A
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Study Makkonen 2000
Methods Randomised, parallel group study conducted in Finland. Patients, providers and assessors not blind. Clear
information about withdrawals: none. Dentist involved in study. Drop outs:0%. Duration: during therapy
(9 wks).
Participants Adults with head and neck cancer. 40 patients eligible, enrolled and evaluated.
Interventions 2 groups, no treatment control versus GM-CSF (150 to 300 ug given subcutaneously daily until last day of
irradiation. Dose depends on body weight).
Outcomes Mucositis on scale 0-2 (0 = no mucositis, 1 = moderate, 2 = severe). Assessment used: day 28. Other reported
outcomes: oral pain on scale 1-4, and patient VAS scale for pain. Evaluated weekly during treatment then 1
and 6 months after therapy, use of analgesic, weight loss, toxicity, survival.
Notes All patients used sucralfate supsension 1 g 6 times daily.
Funding source: pharmaceutical.
Allocation concealment A
Study Nemunaitis 1995
Methods Randomised, parallel group, multicentre study conducted as a USA and Canada. Patient, provider and
assessor blind. Clear information about withdrawals: none.
Dentist not involved in study. Drop outs: 0%. Duration: 1 year.
Participants Adults with mixed cancer receiving BMT, chemotherapy cyclosporine & prednisolone. 109 patients enrolled,
109 completed.
Interventions 2 groups, placebo versus RhGM-CSF (human granulocyte macrophage colony stimulating factor) 250
ug/m2/day IV day 0-20.
Outcomes Mucosistis scored by nurse 3 grades. (Categorised according to WHO criteria for analysis). Assessment used:
day 28. Other reported outcomes: infection, anorexia, diarrohea, hypertension, stomatitis.
Notes Funding source: pharmaceutical.
Allocation concealment A
Study Niibe 1985
Methods Randomised, parallel group study conducted in Japan. Patients, providers and assessors blind. Clear infor-
mation about withdrawals: 4/24 control, 6/23 treatment. Dentist not involved in study. Drop outs: 21%.
Duration: day 1 to end of radiation.
Participants Adults with head and neck cancer. 47 patients enrolled and 37 completed.
Interventions 2 groups, placebo versus amifostine (200 mg per day).
Outcomes Mucositis measured at >= 2 on scale similar to WHO scale. Assessment used: day unclear.
Notes Funding source: unclear.
Allocation concealment A
Study Oberbaum 2001
Methods Randomised, parallel group study conducted in Israel. Patients, providers and assessors blind. Clear infor-
mation about withdrawals: 1/16 control, 1/16 test. Drop outs: 6%. Duration: unclear.
Participants Children and adults with mixed cancer receiving a BMT. 32 consecutive patients enrolled, 30 completed.
Interventions 2 groups, placebo versus traumeel (homeopathic) rinse vigorously 30 sec before swallowing 5/day for a
minimum 14 days.
Outcomes Mucositis WHO scale evaluated every 2 days. Assessment used: day 7.
Notes All patients 2 daily chlorhexidine oral amphotericin B.
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Funding source: pharmaceutical and possibly charity.
Allocation concealment A
Study Okuno 1999
Methods Randomised, parallel group study conducted in USA. Patients, providers and assessors blind. Clear informa-
tion about withdrawals: none. Dentist not involved in study. Drop outs: 0%. Duration: up to 5 weeks after
intral chemotherapy.
Participants Adults with cancer (type unclear). 134 eligible, enrolled and evaluated, but patient assessment only completed
by 124 patients.
Interventions 2 groups, placebo versus glutamine (4 g twice a day, swish for 10 s then swallow).
Outcomes Maximum severity of mucositis over 14 days using 0-4 scale, both physician and patient assessment. Other
reported outcomes: toxicity (no detail). Assessment used: day 14.
Notes All patients used ice chips 5 minutes before 5 FU for 30 minutes.
Funding source: government.
Allocation concealment B
Study Pfeiffer 1990
Methods Randomised, cross-over study conducted in Denmark. Patients, providers and assessors blind. Unclear in-
formation about withdrawals. Dentist not involved in study. Drop outs: 43%. Duration: 14 days.
Participants Adults with mixed cancer (including head and neck). 40 patients enrolled, 23 evaluable.
Interventions 2 groups, placebo versus sulcralfate (1 g 15 ml suspension, swish for 2 min then spit out or swallow).
Outcomes Ulceration or not.
Assessment used: day 14. Other reported outcomes: pain, problems eating.
Notes Funding source: pharmaceutical support for product.
Allocation concealment B
Study Prada 1987
Methods Randomised, parallel group study conducted in Italy. Patients, providers and assessors blind. Unclear infor-
mation about withdrawals. Dentist not involved in study.
Drop outs 10%. Duration: 10 days.
Participants Adults with head and neck cancer. 40 patients eligible and enrolled, 36 evaluated.
Interventions 2 groups, placebo versus benzydamine (120 ml solution of 0.15% benzydamine, 15 ml mouthwash for 5
mins every 3 hours up to max of 6 times daily.
Outcomes Physician evaluation of mucositis on 0 (absent) to 3 (intense or remarkable) scale every day for 10 days.
Assessment used: day 10. Other reported outcomes: global clinical symptomatology, burning, chewing pain,
dysphasia and odynophasia assessed.
Notes Funding source: none.
Allocation concealment B
Study Rahn 1997
Methods Randomised, parallel group study conducted in Germany. Patients and providers not blind, assessors were
blind (c). Clear information about withdrawals: none. Dentist involved in study. Drop outs: 0%. Duration:
until one week after end of radiotherapy.
Participants .Adults with head and neck cancer. 40 patients eligible, enrolled. 2 died but all 40 were evaluated
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Interventions 2 groups, control (sterile water) versus providone iodine rinse (rinsing for 3 mins with 100 ml solution 4
times daily).
Outcomes WHO assessment of mucositis on 0-4 scale. During therapy and at 2, 6 weeks after therapy. Assessment
used: day 28.
Notes All patients received nystatin, dexpanthenol, ratoside and immunoglobin.
Funding source: unclear.
Allocation concealment B
Study Schneider 1999
Methods Randomised, parallel group study conducted in USA. Patients, providers and assessors blind. Clear informa-
tion about withdrawals: none. Dentist involved in study. Drop outs: 0%. Duration:
Participants Adults with head and neck cancer. 14 patients enrolled and evaluated.
Interventions 2 groups, placebo versus filgrastim (subcutaneous injections daily throughout treatment titrated to keep
neutrophil count between 10x 10² and 30X 10³/l).
Outcomes WHO mucositis 0-4 scale, and Hickey mucositis scores. Proportion of patients greater than WHO mucositis
grade 3 presented. Assessment used: week 10.
Notes All patients had oral hygiene instruction. Funding source: pharmaceutical.
Allocation concealment A
Study Shenep 1988
Methods Randomised, parallel group study conducted in USA. Patients, providers and assessors blind. Clear informa-
tion about withdrawals: none. Dentist not involved in study. Drop outs: 0%. Duration: 50 days.
Participants Children with leukaemia. Chemotherapy- remission induction multiagent ANLL-83. 48 patients enrolled
and evaluated.
Interventions 2 groups, placebo versus sucralfate (0.75 mg/kg daily, suspension swished every 6 hours).
Outcomes Mucositis (clinical and patients scales given, 0-4), gram-ve, gram+ve, fungal, all organisms. Assessment used:
day 50. Other reported outcomes: gastroenteritis, gingival bleeding, nutrition, fever, infection, rash.
Notes Clinician’s mucositis score used.
Funding source: government.
Allocation concealment A
Study Shieh 1997
Methods Randomised, parallel group study conducted in China. Patients not blind, unclear whether providers and
assessors blind (c). Clear information about withdrawals: none. Dentist involved in study.
Drop outs: 0%. Duration: 5 weeks.
Participants Adults with head and neck cancer. 30 patients enrolled and evaluated.
Interventions 3 groups (oral care protocols), control given no instructions, E1 given protocol to follow 1 day before
radiotherapy, E2 given protocol to follow 1 week before radiotherapy. Oral care protocol included instructions
on how to brush teeth.
Outcomes Stomatitis free survival (graph). Also means and standard deviations of oral assessment guide (OAG) index,
which includes multiple factors including voice and teeth. Assessment used: day 28.
Notes Funding source: government.
Allocation concealment A
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Study Spijkervet 1989
Methods Randomised, parallel group study conducted in the Netherlands. Patients, providers and assessors blind.
Clear information about withdrawals: none. Dentist involved in study. Drop outs: 0%. Duration: 5 weeks.
Participants Adults with head and neck cancer. 30 patients eligible, enrolled and evaluated.
Interventions 2 groups, placebo versus chlorhexidine spray/rinse (0.1% chlorhexidine 100 ml per day (spray 50 ml) rinsing
3 times with 15 ml).
Outcomes Semiquantitative scoring of mucositis in ’described elsewhere’. Assessed thrice weekly until end of treatment
(at least 50 Gy). Assessment used: day 35. Other reported outcomes: microflora.
Notes Used data from text: 24 patients showed the most severe stage of pseudomembrane formation (12 in placebo
and 12 in test). During radiotherapy daily cleaning of teeth by hygienist.
Funding source: government.
Allocation concealment B
Study Symonds 1996
Methods Randomised, parallel group study conducted in Scotland. Patients, providers and assessors blind. Clear
information about withdrawals: 30/139 control, 24/136 test. Dentist not involved in study. Drop outs: 20%.
Duration: until radiation reaction settled, 8 weeks.
Participants Adults with head and neck cancer. 275 patients enrolled and 221 evaluated.
Interventions 2 groups, placebo versus antibiotic pastille (polymyxin E 2 mg, tobramycin 1.8 mg and amphotericin B 10
mg, 4 times daily from start of radiotherapy).
Outcomes Physician assessment of mucositis (none, patchy confluent). Assessment used: day 56. Other reported out-
comes: patients asked about pain on swallowing and dysphagia, weight loss and compliance.
Notes Funding source: none.
Allocation concealment B
Study Van der Leslie 2001
Methods Randomised, parallel group study conducted in Holland. Patients, providers and assessors blind. Clear
information about withdrawals: none. Dentist involved in study. Drop out: 0%. Duration: until neutrophil
recovery.
Participants Adults with mixed cancer receving BMT or cell stem. 39 patients eligible, 36 enrolled and evaluated.
Interventions 2 groups, placebo versus GM-CSF (300 ug of GM-CSF daily dose in 2% methylocellulose gel, 5 ml gel twice
daily, keep in oral cavity as long as possible then swallow).
Outcomes WHO mucositis scale 0-4. Assessment used: day 14. Other reported outcomes: VAS mucositis pain, OAS
mucositis, required morphine or not, fever, infection treated with antibiotics, duration of netropenia, days
in hospital.
Notes All rinsed with 0.9% saline and in case of inflamation 0.12% chlorhexidine 6 times daily. Funding source:
university, pharmaceutical for intervention.
Allocation concealment A
Study Wahlin 1989
Methods Randomised, parallel group study conducted in Sweden. Patients and providers not blind, assessors blind.
Clear information about withdrawals: 4/14 control, 3/14 test. Dentist involved in study. Drop outs: 0%.
Duration: 21 days.
Participants Children and adults with acute leukaemia at start of chemotherapy. 28 patients enrolled, 14 patients com-
pleted (although mucositis data presented on 28).
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Interventions Control: no treatment versus chlorhexidine (0.2% 10 ml twice daily).
Outcomes Mucositis scored at the level of ulceration. Assessment used: day 28. Other reported outcomes: candidiasis
verified by detecting pseudohypae in smears, days fever, plaque, gingival bleeding, burning sensation.
Notes Data from the first course of chemotherapy used as unable to extract data for second course due to lack of
information about drop outs.
Allocation concealment A
Study Wijers 2001
Methods Randomised, parallel group study conducted in the Netherlands. Patients were not blind, unclear if providers
and assessors were. Unclear information about withdrawals. Dentist involved in study. Drop outs: 32%.
Duration: 3 weeks after radiation.
Participants Adults with head and neck cancer. 114 patients enrolled, 37 refused to continue, 77 completed.
Interventions 2 groups, placebo versus PTA paste containing antibiotics, polymyxin E, tobramycin, amphotericin.
Outcomes Mucositis scored weekly, 5 point scale, Van der Schneren system. Assessment used: day 28 min. Other
reported outcomes: pain, microflora.
Notes Funding source: unclear.
Allocation concealment B
Study Yuen 2001
Methods Randomised, parallel group study conducted in Hong Kong. Patients, providers and assessors not blind.
Clear information on withdrawals: none. Dentist no involved in study. Drop outs: 0%. Duration: 60 days
after BMT.
Participants Adults with mixed cancer receiving BMT, 70 enrolled, 70 evaluated.
Interventions 2 groups no treatment versus Clarithromycin oral 500 mg twice daily or IV 500 mg 12 hourly. Start day -7.
Outcomes Mucositis scoring system not clear. Grade 2 data used. Assessment used: unclear. Other reported outcomes:
toxicity (rash, diarrhoea, liver function), infection, duration of fever, neutropenic fever, use of antibiotics,
parenteral nutrition, growth factors.
Notes Funding Source: none.
Allocation concealment B
(c) indicates from correspondence with authors
Characteristics of excluded studies
Anderson 1998b Data not in suitable form, need number per group for self reported mouth sores for Fig 3 otherwise cannot
use data. (Glutamine versus placebo).
Antonadou 1998 Abstract, insufficient information. (Radiotherapy with or without GM-CSF).
Apaydin 1996 Data not in suitable form. Unclear how mucositis assessed and means (SD) given. (Benzydamine versus
no treatment).
Barasch 1995 Data not in suitable form. Mucositis presented as mean area (SD). (He-Ne Laser versus no treatment).
Bensadoun 1999 Data not in suitable form. Mean (SD) of mucositis grade intensity per week. (He-Ne Laser versus no
treatment).
Chi 1995 Data not in suitable form. Written to authors requesting cross-tabulated data. (GM-CSF versus no treat-
ment).
Costa 1999 Abstract, insufficient information. (Chlorhexidine versus no treatment).
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Cowen 1997 Data in inappropriate form. Daily mucositis index ranging from 0-48 used, with means (SD) presented.
(He-Ne Laser versus no treatment).
Cunningham 1995 Investigating new cancer treatment, Tomudex, with oral mucositis as one of the minor side effects.
Decker-Baummann 1999 Unsuitable treatment outcome for review. (Parental glutamine versus no treatment).
Dudjak 1987 Data not in suitable form. Mean (SD) of mouth and comfort scores. (Two oral care protocols).
Edelman 1998 Not RCT. (Cryotherapy).
Epstein 1986 Mucositis not presented in a useable form, however VAS pain scores presented. (Benzydamine versus
placebo).
Epstein 1989 Data not in suitable form. Mean (SD) for size and area of ulceration presented. (Benzydamine versus
placebo).
Epstein 1992 Data not in suitable form. Mean (SD) for size and area of ulceration presented. (Three groups: chlorhexidine
rinse, nystatin suspension and saline solution).
Epstein 1994 Data not in suitable form. Mean (SD) mucositis scores presented. (Sucralfate versus placebo).
Epstein 1999 Abstract, insufficient information. (Benzydamine versus placebo).
Epstein 2001 Excluded due to mucositis data presented as area under the curve. (Benzydamine versus placebo).
Erkisi 1996 Design fault-intervention confounded by radiotherapy. (G-CSF versus no treatment).
Etiz 1998 Abstract, insufficient information. (Sucralfate versus placebo).
Etiz 2000 Data not in suitable form. Median oral mucositis scores and pain scores presented. (Sucralfate versus
placebo).
Evans 1990 Abstract, insufficient information. (GM-CFS versus placebo).
Fahlke 1999 Not RCT. (Amifostine).
Falcone 2001 Comparing different radiotherapy regimens.
Feber 1996 Data not in suitable form. Oral assessment guide means presented. (Two oral care protocols).
Grotz 2001 Data not in suitable form. Total RTOG scores mean (SD) presented. (Comarin/troxerutine versus placebo).
Hanson 1997 Data not in suitable form. Mucositis mean (SD) graphically presented. (Prostaglandin versus placebo).
Harris 1995 Abstract, insufficient information. (Folinic acid mouthwash versus placebo).
Hickey 1982 Problems with data. 21 patients in total, unclear how many patients per group, but data presented as 67
courses of chemotherapy. (Oral hygiene protocols).
Jebb 1995 Data not in suitable form. Mean (SD) mucositis scores presented. (Glutamine versus placebo).
Karthaus 1998 Problems with the data. 8 patients, 32 chemo cycles and results presented assuming independent. (G-CSF
versus placebo).
Kenny 1990 Data not in suitable form. Oral assessment guide mean (SD) presented. (Two oral care protocols).
Leong 1995 Abstract, insufficient information. (Thymidine versus no treatment).
Levendag 1998 Abstract, insufficient information. (Polyenes versus placebo).
Lievens 1998 Data not in suitable form. Mean (SD) mucositis scores presented graphically. (Sucralfate versus placebo).
Lopez 1994 Data not in suitable form. Number of days with mucositis presented. (Vitamin E versus placebo).
Marcial 1994 Abstract, insufficient information. It states it is an RCT but mentions historical control group. (Low energy
laser versus no treatment).
McGaw 1985 Data not in suitable form. Did not give the numbers in the 2 study groups and data presented as mean
(SD) mucositis index. (Chlorhexidine versus placebo).
McIlroy 1996 Data not in suitable form. Qualitative assessment with no data given. (Polyenes versus placebo).
Nicholl 1995 No suitable outcomes for review. (Amphotericin B - two doses).
Niibe 1985b No clear mucositis index presented. (Amifostine versus placebo).
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Okuno 1997 Major change to protocol half way through study. (Antibiotic lozenge versus placebo).
Okuno 1998 Abstract, insufficient information. (Glutamine versus placebo).
Pfeiffer 1989 Abstract, insufficient information. (Sucralfate versus placebo).
Pouli 1999 Abstract, insufficient information. (GM-CSF versus sodium bicarbonate mouthwash).
Prada 1985 Data not in suitable form. Mean (SD) mucositis scores presented (unsure if RCT). (Benzydamine versus
placebo mouthwash).
Raether 1989 Data not in suitable form. Mean (SD) of ulceration over 7 sites per patient presented. (Chlorhexidine
versus placebo).
Rocke 1993 Patients returning for a second course of chemo were crossed over to alternate group. This only happened
if they experienced no worse than mild mucositis from first course of chemo. Therefore both parallel group
and cross-over trial, also biased as only selected patients crossed over. (Ice chips (30 mins) versus Ice chips
(60 mins)).
Rutkauskas 1993 Data not in suitable form. Mucositis mean (not SD) presented. (Chlorhexidine versus placebo).
Samaranayake 1988 Data not in suitable form. Mean (not SD) presented. (Benzydamine versus chlorhexidine).
Sato 1997 Unsure if RCT and author has not responded to letter requesting further information.
Suc 1999 Abstract, insufficient information. (Chewing gum versus no treatment).
Vacha 1999 Mucositis scores presented, data not in suitable form for the review. (Amifostine versus no treatment).
Verdi 1995 Data not in suitable form. Oral assessment scores (0-24 scale) presented for each patient. (Pentoxifylline
versus placebo).
Vitello 2000 Abstract, insufficient information. (Lidocaine versus dyclone mouthrinses).
Weisdorf 1989 Data not in suitable form. Mean (SD) maximal area of ulceration presented. (Chlorhexidine versus placebo).
Wymenga 1999 Abstract, insufficient information. (TGF-B3 mouthrinse versus no treatment).
A D D I T I O N A L T A B L E S
Table 01. Quality assessment of trials
study concealed allocation outcome blinded explanation drop out
Ahmed 1993 B 1 1
Anderson 1998 B 1 1
Antonado 2002 B 0 1
Attal 1993 A 2 1
Borowski 1994 A 0 1
Bourhis 2000 A 2 0
Brizel 2000 A 0 1 (0)
Bubley 1989 A 1 0
Buntzel 1998a B 2 0
Cartee 1995 A 1 0
Carter 1999 B 1 1
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study concealed allocation outcome blinded explanation drop out
Cascinu 1994 A (B) 0 1
Cengiz 1999 B 2 1
Crawford 1999 B 2 0
Dickson 2000 A (B) 1 1
Dodd 1996 A 1 1
Dozono 1989 A 2 1
Duenas 1996 A (B) 1 1
Erlichman 1988 B 2 0
Ferretti 1988 A (B) 1 0
Ferretti 1990 A 1 0
Fidler 1996 B 1 0
Foote 1994 A 1 1
Frazen 1995 A 1 0
Gurjral 2001 A 0 2
Huang 2000 B 2 1 (0)
Jebb 1994 A (B) 1 0
Katano 1995 B 0 (2) 1
Kaul 1999 B 0 0
Koukourakis 2000 B 0 0
Labar 1993 B 1 1
Leborgne 1997 B 1 0
Loprinzi 1990 A (B) 1 1
Mahood 1991 B 0 0
Makkonen 1994 A 2 1
Makkonen 2000 A 0 1
Nemunaitis 1995 A 1 1
Niibe 1985 A 1 1
Oberbaum 2001 A 1 1
Okuno 1999 B 1 1
Pfeiffer 1990 B 1 0
Prada 1987 B 1 0
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Table 01. Quality assessment of trials (Continued )
study concealed allocation outcome blinded explanation drop out
Rahn 1997 B 1 (2) 1
Schneider 1999 A 1 1
Sheih 1997 A (B) 1 (2) 1
Shenep 1988 A 1 1
Spijkervet 1989 B 1 1
Symonds 1996 B 1 1
Van der Lelie 2001 A (B) 1 1
Wahlin 1989 A (B) 1 1
Wijers 2001 B 2 0
Yuen 2001 B 0 1
Table 02. Data from parallel group studies for comparisons involving cross-over studies
Comparison Treatment n Treatment N Control n Control N OR (95% CI)
glutamine 0 vs 1+
Huang 2000 8 8 9 9 Not estimable
Okuno 1999 46 66 44 68 1.25 (0.61, 2.59)
glutamine 0-1 vs 2+
Dickson 2000 19 29 18 29 1.16 (0.40, 3.39)
Huang 2000 7 8 8 9 0.88 (0.05, 16.75)
Okuno 1999 19 66 20 68 0.97 (0.46, 2.05)
glutamine 0-2 vs 3+
Huang 2000 0 8 4 9 0.07 (0.00, 1.62)
Okuno 1999 4 66 5 68 0.81 (0.21, 3.17)
Ice chips 0 vs 1+
Cascinu 1994 14 44 20 40 0.47 (0.19, 1.13)
Ice chips 0-1 vs 2+
Cascinu 1994 8 44 14 40 0.41 (0.15, 1.13)
Ice chips 0-2 vs 3+
Cascinu 1994 4 44 10 40 0.30 (0.09, 1.05)
sucralfate 0 vs 1+
Cengiz 1999 18 18 10 10 Not estimable
Shenep 1988 24 24 24 24 Not estimable
sucralfate 0-1 vs 2+
Cengiz 1999 9 10 9 18 0.11 (0.01, 1.07)
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Frazen 1995 7 24 15 24 0.25 (0.07, 0.83)
Makkonen 1994 12 20 11 20 1.23 (0.35, 4.31)
Shenep 1988 24 24 24 24 Not estimable
sucralfate 0-2 vs 3+
Carter 1999 22 52 25 50 0.73 (0.34, 1.60)
Cengiz 1999 0 18 2 10 0.09 (0.00, 2.13)
Shenep 1988 17 24 18 24 0.81 (0.23, 2.90)
Table 03. Data from cross-over studies
Comparison test-/control- test-/control+ test+/control- test+/control+ OR (95% CI)
allupurinol mouthrinse 0 vs 1+
Dozono 1989 (low) 1 10 0 4 0.00 (0.00, 0.45)
Dozono 1989 (high) 0 11 1 3 0.09 (0.002, 0.63)
Loprinzi 1990 4 4 2 9 0.50 (0.05, 3.49)
allupurinol mouthrinse 0-1 vs 2+
Dozono 1989 4 11 0 0 0.00 (0.00, 0.40)
Loprinzi 1990 8 4 5 2 1.25 (0.27, 6.30)
allupurinol mouthrinse 0-2 vs 3+
Dozono 1989 8 7 0 0 0.00 (0.00, 0.69)
Loprinzi 1990 15 3 0 1 0.00 (0.00, 2.42)
glutamine 0 vs 1+
Anderson 1998 0 5 0 8 0.00 (0.00, 1.09)
Jebb 1994 (low) 6 2 0 9 0.00 (0.02, 5.33)
Jebb 1994 (high) 0 8 6 3 0.75 (0.21, 2.47)
glutamine 0-1 vs 2+
Jebb 1994 (low) 7 3 0 7 0.00 (0.00, 2.42)
Jebb 1994 (high) 0 10 7 0 0.70 (0.23, 2.04)
glutamine 0-2 vs 3+
Anderson 1998 4 6 0 3 0.00 (0.00, 0.85)
Jebb 1994 (low) 12 0 1 4 Not estimable
Jebb 1994 (high) 8 4 5 0 1.25 (0.27, 6.30)
Ice chips 0 vs 1+
Mahood 1991 9 8 2 8 0.25 (0.03, 1.25)
Ice chips 0-1 vs 2+
Mahood 1991 15 9 2 1 0.22 (0.02, 1.07)
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Table 03. Data from cross-over studies (Continued )
Comparison test-/control- test-/control+ test+/control- test+/control+ OR (95% CI)
Ice chips 0-2 vs 3+
Mahood 1991 19 7 0 1 0.00 (0.00, 0.69)
sucralfate 0-2 vs 3+
Pfeiffer 1990 (low) 4 3 0 16 0.00 (0.00, 2.42)
Pfeiffer 1990 (high) 0 7 4 12 0.57 (0.12, 2.25)
Table 04. Results from parallel group and cross-over studies
Comparison OR (95% CI) Heterogeneity Q
allopurinal mouthrinse 0 vs 1+
Dozono 1989 (low) 0.00 (0.00, 0.45)
Dozono 1989 (high) 0.09 (0.002, 0.63)
Loprinzi 1990 0.50 (0.05, 3.49)
Pooled results (Dozono low) 0.03 (0.00, 12.7) p=0.26 Q=6.68, 1df, p=0.01
(Dozono high) 0.271 (0.05, 1.51) p=0.14 Q=0.88, 1df, p=0.34
allopurinol mouthrinse 0-1 vs 2+
Dozono 1989 0.00 (0.00, 0.40)
Loprinzi 1990 1.25 (0.27, 6.30)
Pooled results 0.05 (0, 49.1) p=0.39 Q=9.93, 1df, p=0.002
allupurinol mouthrinse 0-2 vs 3+
Dozono 1989 0.00 (0.00, 0.69)
Loprinzi 1990 0.00 (0.00, 2.42)
Pooled results 0.00 (0, 0.03) p<0.001 Q=0, 1df, p=1
glutamine 0 vs 1+
Anderson 1998 0.00 (0.00, 1.09)
Huang 2000 Not estimable
Jebb 1994 (low) 0.00 (0.02, 5.33)
Jebb 1994 (high) 0.75 (0.21, 2.47)
Okuno 1999 1.25 (0.61, 2.59)
Pooled results (Jebb low) 0.01 (0.00, 4.24) p=0.14 Q=31.24, 2df, p<0.001
(Jebb high) 0.43 (0.07, 2.72) p=0.37 Q=9.05, 2df, p=0.01
glutamine 0-1 vs 2+
Dickson 2000 1.05 (0.46, 2.41)
Huang 2000 0.98 (0.25, 3.96)
Jebb 1994 (low) 0.00 (0.00, 2.42)
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Jebb 1994 (high) 0.70 (0.23, 2.04)
Okuno 1999 0.98 (0.48, 2.00)
Pooled results(Jebb low) 0.70 (0.20, 2.44) p=0.58 Q=7.22, 3df, p=0.07
(Jebb high) 0.94 (0.55, 1.58) p=0.81 Q=0.44, 3df, p=0.93
glutamine 0-2 vs 3+
Anderson 1998 0.00 (0.00, 0.85)
Huang 2000 0.07 (0.00, 1.62)
Jebb 1994 (high) 1.25 (0.27, 6.307)
Okuno 1999 0.81 (0.21, 3.17)
Pooled results 0.25 (0.03, 2.16) p=0.21 Q=9.45, 3df, p=0.02
Ice chips 0 vs 1+
Cascinu 1994 0.47 (0.19, 1.13)
Mahood 1991 0.25 (0.03, 1.25)
Pooled results 0.42 (0.19, 0.93) p=0.03 Q=0.36, 1df, p=0.55
Ice chips 0-1 vs 2+
Cascinu 1994 0.41 (0.15, 1.13)
Mahood 1991 0.22 (0.02, 1.07)
Pooled results 0.36 (0.15, 0.89) p=0.03 Q=0.30, 1df, p=0.59
Ice chips 0-2 vs 3
Cascinu 1994 0.30 (0.09, 1.05)
Mahood 1991 0.00 (0.00, 0.69)
Pooled results 0.03 (0.00, 6.60) p=0.20 Q=5.94, 1df, p=0.015
sucralfate 0-1 vs 2+
Cengiz 1999 0.73 (0.34, 1.60)
Frazen 1995 0.09 (0.00, 2.13)
Makkonen 1994 0.81 (0.23, 2.90)
Pooled results 0.38 (0.10, 1.48) p=0.16 Q=4.9, 2df, p=0.09
sucralfate 0-2 vs 3+
Carter 1999 0.73 (0.34, 1.60)
Cengiz 1999 0.09 (0.00, 2.13)
Pfeiffer 1990 (low) 0.00 (0.00, 2.42)
Pfeiffer 1990 (high) 0.57 (0.12, 2.25)
Shenep 1988 0.24 (0.06, 1.03)
Pooled results (Pfeiffer low) 0.22 (0.04, 1.19) p=0.08 Q=8.22, 3df, p=0.04
(Pfeiffer high) 0.55 (0.30, 1.02) p=0.056 Q=2.33, 3df, p=0.51
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A N A L Y S E S
Comparison 01. Active treatment versus placebo/no treatment
Outcome title
No. of
studies
No. of
participants Statistical method Effect size
01 mucositis (absent versus
present)
Relative Risk (Random) 95% CI Subtotals only
02 mucositis (0-1 versus 2+) Relative Risk (Random) 95% CI Subtotals only
03 mucositis (0-2 versus 3+) Relative Risk (Random) 95% CI Subtotals only
Comparison 02. Side effects
Outcome title
No. of
studies
No. of
participants Statistical method Effect size
01 amifostine 14 1473 Relative Risk (Random) 95% CI 1.07 [0.75, 1.53]
02 GM-CSF 5 338 Relative Risk (Random) 95% CI 1.25 [0.63, 2.47]
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Analysis 01.01. Comparison 01 Active treatment versus placebo/no treatment, Outcome 01 mucositis
(absent versus present)
Review: Interventions for preventing oral mucositis for patients with cancer receiving treatment
Comparison: 01 Active treatment versus placebo/no treatment
Outcome: 01 mucositis (absent versus present)
Study Treatment Control Relative Risk (Random) Weight Relative Risk (Random)
n/N n/N 95% CI (%) 95% CI
01 aclycovir versus placebo
Bubley 1989 18/27 15/30 100.0 1.33 [ 0.85, 2.08 ]
Subtotal (95% CI) 27 30 100.0 1.33 [ 0.85, 2.08 ]
Total events: 18 (Treatment), 15 (Control)
Test for heterogeneity: not applicable
Test for overall effect z=1.26 p=0.2
02 amifostine versus no treatment
x Antonadou 2002 22/22 23/23 0.0 Not estimable
x Bourhis 2000 12/12 12/12 0.0 Not estimable
Brizel 2000 140/148 152/153 100.0 0.95 [ 0.91, 0.99 ]
Subtotal (95% CI) 182 188 100.0 0.95 [ 0.91, 0.99 ]
Total events: 174 (Treatment), 187 (Control)
Test for heterogeneity: not applicable
Test for overall effect z=2.37 p=0.02
03 antibiotic (pastille or paste) versus placebo
Symonds 1996 85/112 97/109 68.7 0.85 [ 0.75, 0.96 ]
Wijers 2001 32/39 34/38 31.3 0.92 [ 0.76, 1.10 ]
Subtotal (95% CI) 151 147 100.0 0.87 [ 0.79, 0.97 ]
Total events: 117 (Treatment), 131 (Control)
Test for heterogeneity chi-square=0.42 df=1 p=0.52 I?? =0.0%
Test for overall effect z=2.61 p=0.009
04 benzydamine versus placebo
Prada 1987 12/19 16/17 100.0 0.67 [ 0.47, 0.97 ]
Subtotal (95% CI) 19 17 100.0 0.67 [ 0.47, 0.97 ]
Total events: 12 (Treatment), 16 (Control)
Test for heterogeneity: not applicable
Test for overall effect z=2.15 p=0.03
05 camomile versus placebo
Fidler 1996 34/70 40/65 100.0 0.79 [ 0.58, 1.07 ]
Subtotal (95% CI) 70 65 100.0 0.79 [ 0.58, 1.07 ]
Total events: 34 (Treatment), 40 (Control)
Test for heterogeneity: not applicable
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(. . . Continued)
Study Treatment Control Relative Risk (Random) Weight Relative Risk (Random)
n/N n/N 95% CI (%) 95% CI
Test for overall effect z=1.50 p=0.1
06 chlorhexidine versus placebo or no treatment
Dodd 1996 26/112 28/110 27.2 0.91 [ 0.57, 1.45 ]
Ferretti 1988 2/20 8/21 17.2 0.26 [ 0.06, 1.09 ]
Ferretti 1990 11/31 18/28 26.5 0.55 [ 0.32, 0.96 ]
Foote 1994 25/25 26/27 29.1 1.04 [ 0.96, 1.12 ]
Subtotal (95% CI) 188 186 100.0 0.67 [ 0.27, 1.69 ]
Total events: 64 (Treatment), 80 (Control)
Test for heterogeneity chi-square=50.87 df=3 p=<0.0001 I?? =94.1%
Test for overall effect z=0.85 p=0.4
07 folinic acid versus no treatment
Erlichman 1988 44/46 16/61 100.0 3.65 [ 2.38, 5.58 ]
Subtotal (95% CI) 46 61 100.0 3.65 [ 2.38, 5.58 ]
Total events: 44 (Treatment), 16 (Control)
Test for heterogeneity: not applicable
Test for overall effect z=5.96 p<0.00001
08 GM-CSF versus no treatment
Crawford 1999 26/93 48/102 79.7 0.59 [ 0.40, 0.87 ]
Katano 1995 2/7 7/7 20.3 0.29 [ 0.09, 0.92 ]
x Makkonen 2000 20/20 20/20 0.0 Not estimable
Subtotal (95% CI) 120 129 100.0 0.51 [ 0.29, 0.91 ]
Total events: 48 (Treatment), 75 (Control)
Test for heterogeneity chi-square=1.35 df=1 p=0.24 I?? =26.1%
Test for overall effect z=2.27 p=0.02
09 hydrolytic enzymes versus no treatment
Gujral 2001 51/53 46/46 50.8 0.96 [ 0.91, 1.01 ]
Kaul 1999 11/25 25/25 49.2 0.44 [ 0.28, 0.68 ]
Subtotal (95% CI) 78 71 100.0 0.65 [ 0.11, 3.76 ]
Total events: 62 (Treatment), 71 (Control)
Test for heterogeneity chi-square=61.66 df=1 p=<0.0001 I?? =98.4%
Test for overall effect z=0.47 p=0.6
10 oral care protocol versus none
Shieh 1997 12/20 10/10 100.0 0.60 [ 0.42, 0.86 ]
Subtotal (95% CI) 20 10 100.0 0.60 [ 0.42, 0.86 ]
Total events: 12 (Treatment), 10 (Control)
Test for heterogeneity: not applicable
Test for overall effect z=2.80 p=0.005
11 povidone versus water
0.1 0.2 0.5 1 2 5 10
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(. . . Continued)
Study Treatment Control Relative Risk (Random) Weight Relative Risk (Random)
n/N n/N 95% CI (%) 95% CI
Rahn 1997 14/20 20/20 100.0 0.70 [ 0.53, 0.93 ]
Subtotal (95% CI) 20 20 100.0 0.70 [ 0.53, 0.93 ]
Total events: 14 (Treatment), 20 (Control)
Test for heterogeneity: not applicable
Test for overall effect z=2.44 p=0.01
12 prednisone versus placebo
Leborgne 1997 28/32 29/34 100.0 1.03 [ 0.85, 1.24 ]
Subtotal (95% CI) 32 34 100.0 1.03 [ 0.85, 1.24 ]
Total events: 28 (Treatment), 29 (Control)
Test for heterogeneity: not applicable
Test for overall effect z=0.26 p=0.8
13 propantheline versus placebo
Ahmed 1993 2/6 5/6 100.0 0.40 [ 0.12, 1.31 ]
Subtotal (95% CI) 6 6 100.0 0.40 [ 0.12, 1.31 ]
Total events: 2 (Treatment), 5 (Control)
Test for heterogeneity: not applicable
Test for overall effect z=1.51 p=0.1
14 prostaglandin versus placebo
Duenas 1996 8/9 2/7 46.2 3.11 [ 0.94, 10.27 ]
Labar 1993 29/31 29/29 53.8 0.94 [ 0.85, 1.03 ]
Subtotal (95% CI) 40 36 100.0 1.63 [ 0.19, 14.22 ]
Total events: 37 (Treatment), 31 (Control)
Test for heterogeneity chi-square=13.16 df=1 p=0.0003 I?? =92.4%
Test for overall effect z=0.44 p=0.7
15 traumeel versus placebo
Oberbaum 2001 10/15 14/15 100.0 0.71 [ 0.49, 1.05 ]
Subtotal (95% CI) 15 15 100.0 0.71 [ 0.49, 1.05 ]
Total events: 10 (Treatment), 14 (Control)
Test for heterogeneity: not applicable
Test for overall effect z=1.72 p=0.08
0.1 0.2 0.5 1 2 5 10
Favours Treatment Favours Control
45Interventions for preventing oral mucositis for patients with cancer receiving treatment (Review)
Copyright © 2006 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd
Analysis 01.02. Comparison 01 Active treatment versus placebo/no treatment, Outcome 02 mucositis (0-1
versus 2+)
Review: Interventions for preventing oral mucositis for patients with cancer receiving treatment
Comparison: 01 Active treatment versus placebo/no treatment
Outcome: 02 mucositis (0-1 versus 2+)
Study Treatment Control Relative Risk (Random) Weight Relative Risk (Random)
n/N n/N 95% CI (%) 95% CI
01 amifostine versus placebo or no treatment
Antonadou 2002 19/22 23/23 40.6 0.86 [ 0.73, 1.02 ]
x Bourhis 2000 12/12 12/12 0.0 Not estimable
Brizel 2000 108/148 130/153 54.4 0.86 [ 0.76, 0.97 ]
Koukourakis 2000 5/19 12/20 3.0 0.44 [ 0.19, 1.01 ]
Niibe 1985 4/20 7/17 1.9 0.49 [ 0.17, 1.38 ]
Subtotal (95% CI) 221 225 100.0 0.83 [ 0.72, 0.97 ]
Total events: 148 (Treatment), 184 (Control)
Test for heterogeneity chi-square=4.34 df=3 p=0.23 I?? =30.8%
Test for overall effect z=2.41 p=0.02
02 antibiotic paste versus placebo or no treatment
Wijers 2001 26/39 28/38 100.0 0.90 [ 0.68, 1.21 ]
Subtotal (95% CI) 39 38 100.0 0.90 [ 0.68, 1.21 ]
Total events: 26 (Treatment), 28 (Control)
Test for heterogeneity: not applicable
Test for overall effect z=0.67 p=0.5
03 camomile versus placebo
Fidler 1996 12/82 19/82 100.0 0.63 [ 0.33, 1.22 ]
Subtotal (95% CI) 82 82 100.0 0.63 [ 0.33, 1.22 ]
Total events: 12 (Treatment), 19 (Control)
Test for heterogeneity: not applicable
Test for overall effect z=1.38 p=0.2
04 chlorhexidine versus placebo or no treatment
Foote 1994 22/25 21/27 100.0 1.13 [ 0.88, 1.45 ]
Subtotal (95% CI) 25 27 100.0 1.13 [ 0.88, 1.45 ]
Total events: 22 (Treatment), 21 (Control)
Test for heterogeneity: not applicable
Test for overall effect z=0.98 p=0.3
05 folinic acid versus no treatment
Erlichman 1988 30/64 12/61 100.0 2.38 [ 1.35, 4.21 ]
Subtotal (95% CI) 64 61 100.0 2.38 [ 1.35, 4.21 ]
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(. . . Continued)
Study Treatment Control Relative Risk (Random) Weight Relative Risk (Random)
n/N n/N 95% CI (%) 95% CI
Total events: 30 (Treatment), 12 (Control)
Test for heterogeneity: not applicable
Test for overall effect z=2.98 p=0.003
06 GM-CSF versus no treatment
x Makkonen 2000 20/20 20/20 0.0 Not estimable
Nemunaitis 1995 42/53 47/56 100.0 0.94 [ 0.79, 1.13 ]
Subtotal (95% CI) 73 76 100.0 0.94 [ 0.79, 1.13 ]
Total events: 62 (Treatment), 67 (Control)
Test for heterogeneity: not applicable
Test for overall effect z=0.63 p=0.5
07 hydrolytic enzymes versus no treatment
Gujral 2001 26/53 42/46 89.2 0.54 [ 0.40, 0.72 ]
Kaul 1999 2/25 8/25 10.8 0.25 [ 0.06, 1.06 ]
Subtotal (95% CI) 78 71 100.0 0.49 [ 0.30, 0.81 ]
Total events: 28 (Treatment), 50 (Control)
Test for heterogeneity chi-square=1.18 df=1 p=0.28 I?? =15.1%
Test for overall effect z=2.78 p=0.006
08 oral care (intense oral hygiene versus limited oral hygiene)
Borowski 1994 64/75 70/75 100.0 0.91 [ 0.82, 1.02 ]
Subtotal (95% CI) 75 75 100.0 0.91 [ 0.82, 1.02 ]
Total events: 64 (Treatment), 70 (Control)
Test for heterogeneity: not applicable
Test for overall effect z=1.57 p=0.1
09 pentoxifylline versus no treatment
Attal 1993 30/70 30/70 100.0 1.00 [ 0.68, 1.47 ]
Subtotal (95% CI) 70 70 100.0 1.00 [ 0.68, 1.47 ]
Total events: 30 (Treatment), 30 (Control)
Test for heterogeneity: not applicable
Test for overall effect z=0.00 p=1
10 povidone versus water
Rahn 1997 9/20 20/20 100.0 0.45 [ 0.28, 0.73 ]
Subtotal (95% CI) 20 20 100.0 0.45 [ 0.28, 0.73 ]
Total events: 9 (Treatment), 20 (Control)
Test for heterogeneity: not applicable
Test for overall effect z=3.23 p=0.001
11 prednisone versus placebo
Leborgne 1997 16/32 24/34 100.0 0.71 [ 0.47, 1.07 ]
Subtotal (95% CI) 32 34 100.0 0.71 [ 0.47, 1.07 ]
Total events: 16 (Treatment), 24 (Control)
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(. . . Continued)
Study Treatment Control Relative Risk (Random) Weight Relative Risk (Random)
n/N n/N 95% CI (%) 95% CI
Test for heterogeneity: not applicable
Test for overall effect z=1.65 p=0.1
12 systemic antibiotic clarithromycin versus no treatment
Yuen 2001 18/35 26/35 100.0 0.69 [ 0.48, 1.01 ]
Subtotal (95% CI) 35 35 100.0 0.69 [ 0.48, 1.01 ]
Total events: 18 (Treatment), 26 (Control)
Test for heterogeneity: not applicable
Test for overall effect z=1.91 p=0.06
0.1 0.2 0.5 1 2 5 10
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Analysis 01.03. Comparison 01 Active treatment versus placebo/no treatment, Outcome 03 mucositis (0-2
versus 3+)
Review: Interventions for preventing oral mucositis for patients with cancer receiving treatment
Comparison: 01 Active treatment versus placebo/no treatment
Outcome: 03 mucositis (0-2 versus 3+)
Study Treatment Control Relative Risk (Random) Weight Relative Risk (Random)
n/N n/N 95% CI (%) 95% CI
01 amifostine versus no treatment
Antonadou 2002 5/22 18/23 23.6 0.29 [ 0.13, 0.65 ]
Bourhis 2000 11/12 11/12 33.4 1.00 [ 0.79, 1.27 ]
Brizel 2000 52/148 60/153 32.7 0.90 [ 0.67, 1.20 ]
Buntzel 1998 0/14 12/14 5.3 0.04 [ 0.00, 0.62 ]
Koukourakis 2000 0/19 6/20 5.1 0.08 [ 0.00, 1.34 ]
Subtotal (95% CI) 215 222 100.0 0.54 [ 0.27, 1.06 ]
Total events: 68 (Treatment), 107 (Control)
Test for heterogeneity chi-square=26.01 df=4 p=<0.0001 I?? =84.6%
Test for overall effect z=1.79 p=0.07
02 antibiotic paste versus placebo
Wijers 2001 15/39 18/38 100.0 0.81 [ 0.48, 1.37 ]
Subtotal (95% CI) 39 38 100.0 0.81 [ 0.48, 1.37 ]
Total events: 15 (Treatment), 18 (Control)
Test for heterogeneity: not applicable
Test for overall effect z=0.79 p=0.4
0.1 0.2 0.5 1 2 5 10
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(. . . Continued)
Study Treatment Control Relative Risk (Random) Weight Relative Risk (Random)
n/N n/N 95% CI (%) 95% CI
03 camomile versus placebo
Fidler 1996 8/82 7/82 100.0 1.14 [ 0.43, 3.01 ]
Subtotal (95% CI) 82 82 100.0 1.14 [ 0.43, 3.01 ]
Total events: 8 (Treatment), 7 (Control)
Test for heterogeneity: not applicable
Test for overall effect z=0.27 p=0.8
04 chlorhexidine versus placebo or no treatment
Foote 1994 14/25 15/27 28.7 1.01 [ 0.62, 1.64 ]
Spijkervet 1989 12/15 12/15 52.5 1.00 [ 0.70, 1.43 ]
Wahlin 1989 8/14 9/14 18.8 0.89 [ 0.49, 1.62 ]
Subtotal (95% CI) 54 56 100.0 0.98 [ 0.76, 1.27 ]
Total events: 34 (Treatment), 36 (Control)
Test for heterogeneity chi-square=0.13 df=2 p=0.94 I?? =0.0%
Test for overall effect z=0.15 p=0.9
05 folinic acid versus no treatment
Erlichman 1988 4/64 0/61 100.0 8.58 [ 0.47, 156.17 ]
Subtotal (95% CI) 64 61 100.0 8.58 [ 0.47, 156.17 ]
Total events: 4 (Treatment), 0 (Control)
Test for heterogeneity: not applicable
Test for overall effect z=1.45 p=0.1
06 GM-CSF versus placebo
Cartee 1995 15/36 2/9 24.0 1.88 [ 0.52, 6.76 ]
Nemunaitis 1995 4/53 16/56 27.4 0.26 [ 0.09, 0.74 ]
Schneider 1999 1/8 3/6 16.0 0.25 [ 0.03, 1.85 ]
Van der Leslie 2001 11/18 8/18 32.6 1.38 [ 0.73, 2.59 ]
Subtotal (95% CI) 115 89 100.0 0.72 [ 0.25, 2.08 ]
Total events: 31 (Treatment), 29 (Control)
Test for heterogeneity chi-square=10.78 df=3 p=0.01 I?? =72.2%
Test for overall effect z=0.61 p=0.5
07 hydrolytic enzymes versus no treatment
Gujral 2001 3/53 15/46 86.6 0.17 [ 0.05, 0.56 ]
Kaul 1999 0/25 2/25 13.4 0.20 [ 0.01, 3.97 ]
Subtotal (95% CI) 78 71 100.0 0.18 [ 0.06, 0.53 ]
Total events: 3 (Treatment), 17 (Control)
Test for heterogeneity chi-square=0.01 df=1 p=0.93 I?? =0.0%
Test for overall effect z=3.10 p=0.002
08 oral care (intense oral hygiene versus limited oral hygiene)
Borowski 1994 49/75 58/75 100.0 0.84 [ 0.69, 1.04 ]
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Study Treatment Control Relative Risk (Random) Weight Relative Risk (Random)
n/N n/N 95% CI (%) 95% CI
Subtotal (95% CI) 75 75 100.0 0.84 [ 0.69, 1.04 ]
Total events: 49 (Treatment), 58 (Control)
Test for heterogeneity: not applicable
Test for overall effect z=1.61 p=0.1
09 povidone versus water
Rahn 1997 4/20 13/20 100.0 0.31 [ 0.12, 0.78 ]
Subtotal (95% CI) 20 20 100.0 0.31 [ 0.12, 0.78 ]
Total events: 4 (Treatment), 13 (Control)
Test for heterogeneity: not applicable
Test for overall effect z=2.47 p=0.01
10 prednisone versus placebo
Leborgne 1997 3/32 5/34 100.0 0.64 [ 0.17, 2.45 ]
Subtotal (95% CI) 32 34 100.0 0.64 [ 0.17, 2.45 ]
Total events: 3 (Treatment), 5 (Control)
Test for heterogeneity: not applicable
Test for overall effect z=0.65 p=0.5
11 prostoglandin versus placebo
Labar 1993 17/31 15/29 100.0 1.06 [ 0.66, 1.70 ]
Subtotal (95% CI) 31 29 100.0 1.06 [ 0.66, 1.70 ]
Total events: 17 (Treatment), 15 (Control)
Test for heterogeneity: not applicable
Test for overall effect z=0.24 p=0.8
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Analysis 02.01. Comparison 02 Side effects, Outcome 01 amifostine
Review: Interventions for preventing oral mucositis for patients with cancer receiving treatment
Comparison: 02 Side effects
Outcome: 01 amifostine
Study Treatment Control Relative Risk (Random) Weight Relative Risk (Random)
n/N n/N 95% CI (%) 95% CI
01 survival at 24 months
Brizel 2000 30/36 22/30 29.1 1.14 [ 0.88, 1.47 ]
Subtotal (95% CI) 36 30 29.1 1.14 [ 0.88, 1.47 ]
Total events: 30 (Treatment), 22 (Control)
Test for heterogeneity: not applicable
Test for overall effect z=0.96 p=0.3
02 recurrence at 18 months after cancer treatment
Antonadou 2002 4/22 6/23 7.9 0.70 [ 0.23, 2.14 ]
Brizel 2000 28/80 28/88 23.1 1.10 [ 0.72, 1.69 ]
Subtotal (95% CI) 102 111 30.9 1.04 [ 0.70, 1.55 ]
Total events: 32 (Treatment), 34 (Control)
Test for heterogeneity chi-square=0.56 df=1 p=0.46 I?? =0.0%
Test for overall effect z=0.18 p=0.9
03 incomplete response to radiotherapy
Antonadou 2002 2/22 5/23 4.7 0.42 [ 0.09, 1.94 ]
Koukourakis 2000 5/12 6/12 11.2 0.83 [ 0.35, 2.00 ]
Subtotal (95% CI) 34 35 16.0 0.70 [ 0.33, 1.50 ]
Total events: 7 (Treatment), 11 (Control)
Test for heterogeneity chi-square=0.63 df=1 p=0.43 I?? =0.0%
Test for overall effect z=0.91 p=0.4
04 delay to radiotherapy
Koukourakis 2000 5/19 12/20 12.0 0.44 [ 0.19, 1.01 ]
Subtotal (95% CI) 19 20 12.0 0.44 [ 0.19, 1.01 ]
Total events: 5 (Treatment), 12 (Control)
Test for heterogeneity: not applicable
Test for overall effect z=1.94 p=0.05
05 hypotension
Antonadou 2002 3/22 0/23 1.5 7.30 [ 0.40, 133.75 ]
Brizel 2000 4/148 0/153 1.4 9.30 [ 0.51, 171.28 ]
Subtotal (95% CI) 170 176 2.9 8.24 [ 1.05, 64.52 ]
Total events: 7 (Treatment), 0 (Control)
Test for heterogeneity chi-square=0.01 df=1 p=0.91 I?? =0.0%
Test for overall effect z=2.01 p=0.04
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Study Treatment Control Relative Risk (Random) Weight Relative Risk (Random)
n/N n/N 95% CI (%) 95% CI
06 nausea
Antonadou 2002 1/22 0/23 1.2 3.13 [ 0.13, 72.99 ]
Bourhis 2000 1/12 0/12 1.3 3.00 [ 0.13, 67.06 ]
Brizel 2000 4/148 1/153 2.5 4.14 [ 0.47, 36.57 ]
Subtotal (95% CI) 182 188 5.0 3.57 [ 0.76, 16.85 ]
Total events: 6 (Treatment), 1 (Control)
Test for heterogeneity chi-square=0.04 df=2 p=0.98 I?? =0.0%
Test for overall effect z=1.61 p=0.1
07 vomiting
Antonadou 2002 1/22 0/23 1.2 3.13 [ 0.13, 72.99 ]
Bourhis 2000 1/12 0/12 1.3 3.00 [ 0.13, 67.06 ]
Brizel 2000 8/148 0/153 1.5 17.57 [ 1.02, 301.71 ]
Subtotal (95% CI) 182 188 4.0 5.92 [ 1.03, 33.91 ]
Total events: 10 (Treatment), 0 (Control)
Test for heterogeneity chi-square=1.01 df=2 p=0.60 I?? =0.0%
Test for overall effect z=2.00 p=0.05
Total (95% CI) 725 748 100.0 1.07 [ 0.75, 1.53 ]
Total events: 97 (Treatment), 80 (Control)
Test for heterogeneity chi-square=18.65 df=13 p=0.13 I?? =30.3%
Test for overall effect z=0.37 p=0.7
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Analysis 02.02. Comparison 02 Side effects, Outcome 02 GM-CSF
Review: Interventions for preventing oral mucositis for patients with cancer receiving treatment
Comparison: 02 Side effects
Outcome: 02 GM-CSF
Study Treatment Control Relative Risk (Random) Weight Relative Risk (Random)
n/N n/N 95% CI (%) 95% CI
01 survival 24 months
Makkonen 2000 11/20 15/20 31.4 0.73 [ 0.46, 1.17 ]
Subtotal (95% CI) 20 20 31.4 0.73 [ 0.46, 1.17 ]
Total events: 11 (Treatment), 15 (Control)
Test for heterogeneity: not applicable
Test for overall effect z=1.29 p=0.2
02 survival 12 months
Nemunaitis 1995 28/53 35/56 34.0 0.85 [ 0.61, 1.17 ]
Subtotal (95% CI) 53 56 34.0 0.85 [ 0.61, 1.17 ]
Total events: 28 (Treatment), 35 (Control)
Test for heterogeneity: not applicable
Test for overall effect z=1.01 p=0.3
03 relapse within 1 year
Nemunaitis 1995 10/53 6/56 21.6 1.76 [ 0.69, 4.51 ]
Subtotal (95% CI) 53 56 21.6 1.76 [ 0.69, 4.51 ]
Total events: 10 (Treatment), 6 (Control)
Test for heterogeneity: not applicable
Test for overall effect z=1.18 p=0.2
04 nausea
Makkonen 2000 3/20 1/20 7.7 3.00 [ 0.34, 26.45 ]
Subtotal (95% CI) 20 20 7.7 3.00 [ 0.34, 26.45 ]
Total events: 3 (Treatment), 1 (Control)
Test for heterogeneity: not applicable
Test for overall effect z=0.99 p=0.3
05 local skin reaction
Makkonen 2000 13/20 0/20 5.2 27.00 [ 1.71, 425.36 ]
Subtotal (95% CI) 20 20 5.2 27.00 [ 1.71, 425.36 ]
Total events: 13 (Treatment), 0 (Control)
Test for heterogeneity: not applicable
Test for overall effect z=2.34 p=0.02
Total (95% CI) 166 172 100.0 1.25 [ 0.63, 2.47 ]
Total events: 65 (Treatment), 57 (Control)
Test for heterogeneity chi-square=14.34 df=4 p=0.006 I?? =72.1%
Test for overall effect z=0.65 p=0.5
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